

W. Kimryn Rathmell, MD, PhD

Address: 1161 21st St. South
Medical Center North, Suite D3100
Nashville, TN 37232
Phone: 615-343-0250
Fax: 615-343-7602
Email: Kimryn.Rathmell@Vanderbilt.Edu

Birthplace: Omaha, NE, DOB: Nov. 3, 1969

Education:

08/2003-07/2004 Postdoctoral Training, University of North Carolina at Chapel Hill
Mentor: Terry Van Dyke,
07/2001-07/2003 Postdoctoral Training, University of Pennsylvania,
Mentor: M. Celeste Simon
06/2000-06/2004 Fellow, University of Pennsylvania, Medical Oncology
06/1999-06/2000 Resident, University of Pennsylvania, Internal Medicine
07/1998-06/1999 Intern, University of Chicago, Internal Medicine
08/1991-06/1998 MD, Stanford University, Medicine
07/1993-09/1996 PhD, Stanford University, Biophysics
08/1987-06/1991 BS, University of Northern Iowa, Biology, Highest Honors
08/1987-06/1991 BA, University of Northern Iowa, Chemistry, Highest Honors, top graduate

Positions Held:

08/2020-present Chair, Department of Medicine, Vanderbilt University Medical Center (interim, 01/2020-07/2020)
08/2020-present Physician-in-Chief, Vanderbilt University Medical Center, (interim, 01/2020-07/2020)
07/2019-present Deputy Director for Research Integration and Career Development, Vanderbilt-Ingram Cancer Center
07/2015-08/2020 Cornelius A. Craig Professor, Department of Medicine, Vanderbilt University Medical Center
04/2017-present Professor, Biochemistry Department, by secondary appointment, Vanderbilt University
09/2015-01/2020 Director, Division of Hematology and Oncology, Vanderbilt University Medical Center
09/2015-07/2017 Professor, Cancer Biology Department, by secondary appointment, Vanderbilt University (08/2017, department was disbanded)
07/2015-present Research Associate Professor (Adjunct), Department of Medicine, University of North Carolina at Chapel Hill

09/2014-06/2015	Associate Director for Training and Education, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill
09/2014-06/2015	Clinical Associate Professor, Department of Urology, University of North Carolina at Chapel Hill
07/2013-06/2015	Alexander Professor for Translational Science, University of North Carolina at Chapel Hill
10/2010-06/2015	Associate Professor with tenure, Department of Medicine, Division of Hematology and Oncology, University of North Carolina at Chapel Hill
10/2010-06/2015	Associate Professor, Department of Genetics, University of North Carolina at Chapel Hill (secondary)
06/2011-06/2015	MSTP: Associate Director, Director for Translational Research, University of North Carolina at Chapel Hill
07/2010-06/2014	Co-Director, HHMI Med→Grad Translational Medicine Program, University of North Carolina at Chapel Hill
01/2011-01/2012	Graduate Faculty Member, Department of Pharmacology and Cancer Biology, Duke University
07/2008-10/2010	Adjunct Assistant Professor, Department of Genetics, University of North Carolina at Chapel Hill
12/2004-10/2010	Assistant Professor, Department of Medicine, Division of Hematology and Oncology, University of North Carolina at Chapel Hill
08/2003-11/2004	Instructor, Department of Medicine, University of North Carolina at Chapel Hill

Licensure and Professional Certification:

2004-2024	Board Certification Oncology (active)
2001-2011	Board Certification Internal Medicine (inactive)
2015-present	Medical License Tennessee Medical Board, 53185 (active)
2003-2015	Medical License North Carolina Medical Board, 2003-061123 (inactive)
2000-2003	Medical License Pennsylvania Commonwealth, MT045523T (inactive)

Honors and Awards:

2021	AAAS, elected Fellow
2020	AACR Team Science Award (the Cancer Genome Atlas)
2019	Eugene P. Schoenfeld Award for Outstanding Contributions in Kidney Cancer
2019	Louisa Nelson Award, honoring women of achievement, inspiration, and vision in Nashville
2018	Association of American Physicians (AAP) induction
2018	AACR-Kure-IT Award for Immunotherapy in Kidney Cancer
2017-2021	ASCI Vice President, President-elect 2018, President in 2019
2015	Leland Wilson Chemistry Endowed Lectureship, University of Northern Iowa
2014	UNC ACCLAIM Leadership Development Program
2014	Alpha Omega Alpha (AOA) induction
2012	Ruth and Philip Hettelman Award for Scholarly Achievement

2011	American Society of Clinical Investigators (ASCI) induction
2011	Award for Outstanding Achievement, 14th World Congress on Cancer
2010	AACR Landon INNOVATOR Award for Personalized Medicine
2010	ASCO Leadership Development Award
2009-2017	Best Doctors in America
2006-2009	Doris Duke Clinical Scientist Development Award
2006-2007	American Cancer Society Research Scholar Award
2004, 2008	Lineberger Clinical/Translational Medicine Research Award
2004	UNC School of Medicine Junior Faculty Grant
2004-2008	Forbeck Forum Scholar Award
2003-2008	National Cancer Institute Career Development Award K08 CA98410
2003-2005	V Scholar Award, The V Foundation for Cancer Research
1996-1998	Medical Scientist Training Program, Stanford University
1996	PEO Scholar Award
1994-1996	Howard Hughes Predoctoral Fellowship, Stanford University
1992-1997	Ruth G. White PEO Scholarship
1991-1994	Medical Scholars Research Grant, Stanford University
1991	Purple and Old Gold Award, University of Northern Iowa, Chemistry (Top Graduate in a Major)
1991	Graduate with Highest Honors, University of Northern Iowa
1990	J.S. Latta Biology Research Grant, University of Northern Iowa
1989	J.S. Latta Biology Scholarship, University of Northern Iowa
1987-1991	Presidential Scholar, University of Northern Iowa

Bibliography:

Original Research (peer reviewed)

1. Reinfeld BI, Madden MZ, Wolf MW, Chytil A, Bader JE, Patterson AR, Sugiura A, Cohen AS, Ali A, Do BT, Muir A, Lewis CA, Hongo RA, Young KL, Brown RE, Todd VM, Huffstater T, Abraham A, O'Neil RT, Wilson MH, Xin F, Tantawy MN, Merryman WD, Johnson RW, Williams CS, Mason EF, Mason FM, Beckermann KE, Vander Heiden MG, Manning HC, Rathmell JC*, **Rathmell WK***. Cell Programmed Nutrient Partitioning in the Tumor Microenvironment. *Nature*. 2021. DOI : 10.1038/s41586-021-03442-1. *In press*.
2. Wood CG, Ferguson JE 3rd, Parker JS, Moore DT, Whisenant JG, Maygarden SJ, Wallen EM, Kim WY, Milowsky MI, Beckermann KE, Davis NB, Haake SM, Karam JA, Bortone DS, Vincent BG, Powles T, **Rathmell WK**. Neoadjuvant pazopanib and molecular analysis of tissue response in renal cell carcinoma. *JCI Insight*. 2020 Nov 19;5(22):e132852. PMID: 33208553; PMCID: PMC7710285.
3. Seervai RNH, Jangid RK, Karki M, Tripathi DN, Jung SY, Kearns SE, Verhey KJ, Cianfrocco MA, Millis BA, Tyska MJ, Mason FM, **Rathmell WK**, Park IY, Dere R, Walker CL. The Huntingtin-interacting protein SETD2/HYPB is an actin lysine methyltransferase. *Sci Adv*. 2020 Oct 2;6(40):eabb7854. doi: 10.1126/sciadv.abb7854. PMID: 33008892.

4. Beckermann KE, Hongo R, Ye X, Young K, Carbonell K, Healey DCC, Siska PJ, Barone S, Roe CE, Smith CC, Vincent BG, Mason FM, Irish JM, **Rathmell WK**, Rathmell JC. CD28 costimulation drives tumor-infiltrating T cell glycolysis to promote inflammation. *JCI Insight*. 2020 Aug 20;5(16):e138729. doi: 10.1172/jci.insight.138729. PMID: 32814710; PMCID: PMC7455120.
5. Eulitt PJ, Altun E, Sheikh A, Wong TZ, Woods ME, Rose TL, Wallen EM, Pruthi RS, Smith AB, Nielsen ME, Whang YE, Kim WY, Godley PA, Basch EM, David GU, Ramirez J, Deal AM, **Rathmell WK**, Chen RC, Bjurlin MA, Lin W, Lee JK, Milowsky MI. Pilot Study of [18F] Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)/Magnetic Resonance Imaging (MRI) for Staging of Muscle-invasive Bladder Cancer (MIBC). *Clin Genitourin Cancer*. 2020 Oct;18(5):378-386.e1. doi: 10.1016/j.clgc.2020.02.008. Epub 2020 Mar 6. PMID: 32147364.
6. Vilgelm AE, Bergdorf K, Wolf M, Bharti V, Shattuck-Brandt R, Blevins A, Jones C, Phifer C, Lee M, Lowe C, Hongo R, Boyd K, Netterville J, Rohde S, Idrees K, Bauer JA, Westover D, Reinfeld B, Baregamian N, Richmond A, **Rathmell WK**, Lee E, McDonald OG, Weiss VL. Fine-Needle Aspiration-Based Patient-Derived Cancer Organoids. *iScience*. 2020 Aug 21;23(8):101408. doi: 10.1016/j.isci.2020.101408. Epub 2020 Jul 24. PMID: 32771978; PMCID: PMC7415927.
7. de Cubas AA, Dunker W, Zaninovich A, Hongo RA, Bhatia A, Panda A, Beckermann KE, Bhanot G, Ganesan S, Karijolic J, **Rathmell WK**. DNA hypomethylation promotes transposable element expression and activation of immune signaling in renal cell cancer. *JCI Insight*. 2020 Jun 4;5(11):e137569. doi: 10.1172/jci.insight.137569. PMID: 32493845; PMCID: PMC7308050.
8. Liu XD, Kong W, Peterson CB, McGrail DJ, Hoang A, Zhang X, Lam T, Pilie PG, Zhu H, Beckermann KE, Haake SM, Isgandrova S, Martinez-Moczygemba M, Sahni N, Tannir NM, Lin SY, **Rathmell WK**, Jonasch E. PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma. *Nat Commun*. 2020 May 1;11(1):2135. PMID: 32358509 PMCID: PMC7195420
9. Raddatz MA, Huffstater T, Bersi MR, Reinfeld BI, Madden MZ, Booton SE, **Rathmell WK**, Rathmell JC, Lindman BR, Madhur MS, Merryman WD. Macrophages Promote Aortic Valve Cell Calcification and Alter STAT3 Splicing. *Arterioscler Thromb Vasc Biol*. 2020 Jun;40(6):e153-e165. doi: 10.1161/ATVBAHA.120.314360. Epub 2020 Apr 16. PMID: 32295422; PMCID: PMC7285853.
10. **Rathmell, WK**, Brown, NJ, Kilburg, RR. Transformation to academic leadership: The role of mentorship and executive coaching. *Consulting Psychology Journal: Practice and Research*, 2019, 71(3), 141-160. NIHMSID 1019529
11. Ornstein MC, Pal SK, Wood LS, Tomer JM, Hobbs BP, Jia XS, Allman KD, Martin A, Olencki T, Davis NB, Gilligan TD, Mortazavi A, **Rathmell WK**, Garcia JA, Rini BI. Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study. *Lancet Oncol*. 2019 Aug 16. 2019 Oct;20(10):1386-1394. PMID: 31427205
12. Terzo EA, Lim AR, Chytil A, Chiang YC, Farmer L, Gessner KH, Walker CL, Jansen VM, **Rathmell WK**. SETD2 loss sensitizes cells to PI3K β and AKT inhibition. *Oncotarget*. 2019

Jan 18;10(6):647-659. PMID: 30774762. PMCID: PMC6363018. Correction: *Oncotarget*. 2019 Oct 29;10(59):6391-6392.

13. Johnson MO, Wolf MM, Madden MZ, Andrejeva G, Sugiura A, Contreras DC, Maseda D, Liberti MV, Paz K, Kishton RJ, Johnson ME, de Cubas AA, Wu P, Li G, Zhang Y, Newcomb DC, Wells AD, Restifo NP, **Rathmell WK**, Locasale JW, Davila ML, Blazar BR, Rathmell JC. Distinct Regulation of Th17 and Th1 Cell Differentiation by Glutaminase-Dependent Metabolism. *Cell*. 2018 Dec 13;175(7):1780-1795.e19. PMID: 30392958. PMCID: PMC6361668
14. Msaouel P, Hong AL, Mullen EA, Atkins MB, Walker CL, Lee CH, Carden MA, Genovese G, Linehan WM, Rao P, Merino MJ, Grodman H, Dome JS, Fernandez CV, Geller JI, Apolo AB, Daw NC, Hodges HC, Moxey-Mims M, Wei D, Bottaro DP, Staehler M, Karam JA, **Rathmell WK**, Tannir NM. Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients with Renal Medullary Carcinoma. *Clin Genitourin Cancer*. 2018 Sep 12. pii: S1558-7673(18)30384-7. doi: 10.1016/j.clgc.2018.09.005. [Epub ahead of print] PMID: 30287223
15. Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, Zhao S, Das S, Beckermann KE, Ha L, **Rathmell WK**, Ancell KK, Balko JM, Bowman C, Davis EJ, Chism DD, Horn L, Long GV, Carlino MS, Lebrun-Vignes B, Eroglu Z, Hassel JC, Menzies AM, Sosman JA, Sullivan RJ, Moslehi JJ, Johnson DB. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. *JAMA Oncol*. 2018 Sep 13. doi: 10.1001/jamaoncol.2018.3923. [Epub ahead of print] PMID: 30242316
16. McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B, Fong L, Joseph RW, Pal SK, Reeves JA, Sznol M, Hainsworth J, **Rathmell WK**, Stadler WM, Hutson T, Gore ME, Ravaud A, Bracarda S, Suárez C, Danielli R, Gruenwald V, Choueiri TK, Nickles D, Jhunjhunwala S, Piauult-Louis E, Thobhani A, Qiu J, Chen DS, Hegde PS, Schiff C, Fine GD, Powles T. Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. *Nat Med*. 2018 Oct 5. [epub ahead of print] PMID: 30291359
Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. *Nat Med*. 2018 Oct 5. doi: 10.1038/s41591-018-0235-z. [Epub ahead of print] PMID: 30291359
17. Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, Zhao S, Das S, Beckermann KE, Ha L, **Rathmell WK**, Ancell KK, Balko JM, Bowman C, Davis EJ, Chism DD, Horn L, Long GV, Carlino MS, Lebrun-Vignes B, Eroglu Z, Hassel JC, Menzies AM, Sosman JA, Sullivan RJ, Moslehi JJ, Johnson DB. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. *JAMA Oncol*. 2018 Sep 13. doi: 10.1001/jamaoncol.2018.3923. [Epub ahead of print] PMID: 30242316
18. Smith CC, Beckermann KE, Bortone DS, de Cubas AA, Bixby LM, Lee SJ, Panda A, Ganesan S, Bhanot G, Wallen EM, Milowsky MI, Kim WY, **Rathmell WK**, Swanstrom R, Parker JS, Serody JS, Selitsky SR, Vincent BG. Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma. *J Clin Invest*. 2018 Nov 1;128(11):4804-4820. PMID: 30137025

19. Panda A, de Cubas AA, Stein M, Riedlinger G, Kra J, Mayer T, Smith CC, Vincent BG, Serody JS, Beckermann KE, Ganesan S, Bhanot G, **Rathmell WK**. Endogenous retrovirus expression is associated with response to immune checkpoint blockade in clear cell renal cell carcinoma. *JCI Insight*. 2018 Aug 23;3(16). PMID: 30135306
20. Rojas, JD, Papadopoulou, V, Czernuszewicz, TJ, Rajamahendiran, RM, Chytil, A, Chiang, Y-C, Chong, DC, Bautch, VL, **Rathmell, WK**, Aylward, S, Gessner, RC, Dayton, PA. Ultrasound measurement of vascular density to evaluate response to anti-angiogenic therapy in renal cell carcinoma. *IEEE Transactions in Biomedical Engineering*. In press.
21. Zhang J, Wu T, Simon J, Takada M, Saito R, Fan C, Liu XD, Jonasch E, Xie L, Chen X, Yao X, Teh BT, Tan P, Zheng X, Li M, Lawrence C, Fan J, Geng J, Liu X, Hu L, Wang J, Liao C, Hong K, Zurlo G, Parker JS, Auman JT, Perou CM, **Rathmell WK**, Kim WY, Kirschner MW, Kaelin WG Jr, Baldwin AS, Zhang Q. VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma. *Science*. 2018 Jul 20;361(6399):290-295. PMID: 30026228
22. McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B, Fong L, Joseph RW, Pal SK, Reeves JA, Sznol M, Hainsworth J, **Rathmell WK**, Stadler WM, Hutson T, Gore ME, Ravaud A, Bracarda S, Suárez C, Danielli R, Gruenwald V, Choueiri TK, Nickles D, Jhunjhunwala S, Piault-Louis E, Thobhani A, Qiu J, Chen DS, Hegde PS, Schiff C, Fine GD, Powles T. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. *Nat Med*. 2018 Jun;24(6):749-757. PMID: 29867230
23. Yin Q, Hung SC, **Rathmell WK**, Shen L, Wang L, Lin W, Fielding JR, Khandani AH, Woods ME, Milowsky MI, Brooks SA, Wallen EM, Shen D. Integrative radiomics expression predicts molecular subtypes of primary clear cell renal cell carcinoma. *Clin Radiol*. 2018 May 22. pii: S0009-9260(18)30168-5.. PMID:29801658
24. Chiang YC, Park IY, Terzo EA, Tripathi DN, Mason FM, Fahey CC, Karki M, Shuster CB, Sohn BH, Chowdhury P, Powell RT, Ohi R, Tsai YS, de Cubas AA, Khan A, Davis IJ, Strahl BD, Parker JS, Dere R, Walker CL, **Rathmell WK**. SETD2 Haploinsufficiency for Microtubule Methylation Is an Early Driver of Genomic Instability in Renal Cell Carcinoma. *Cancer Res*. 2018 Jun 15;78(12):3135-3146. PMID: 29724720
25. Kuwahara Y, Kennedy LM, Karnezis AN, Mora-Blanco EL, Rogers AB, Fletcher CD, Huntsman DG, Roberts CWM, **Rathmell WK**, Weissman BE. High Frequency of Ovarian Cyst Development in Vhl2B/+;Snf5+/- Mice. *Am J Pathol*. 2018 Apr 22. pii: S0002-9440(17)31178-1. PMID: 29684361
26. Jonasch E, Slack RS, Geynisman DM, Hasanov E, Milowsky MI, **Rathmell WK**, Stovall S, Juarez D, Gilchrist TR, Pruitt L, Ornstein MC, Plimack ER, Tannir NM, Rini BI. Phase II Study of Two Weeks on, One Week off Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma. *J Clin Oncol*. 2018 Jun 1;36(16):1588-1593. PMID: 29641297
27. Ricketts CJ, De Cubas AA, Fan H, Smith CC, Lang M, Reznik E, Bowlby R, Gibb EA, Akbani R, Beroukhi R, Bottaro DP, Choueiri TK, Gibbs RA, Godwin AK, Haake S, Hakimi AA, Henske EP, Hsieh JJ, Ho TH, Kanchi RS, Krishnan B, Kwiatkowski DJ, Lui W, Merino MJ, Mills GB, Myers J, Nickerson ML, Reuter VE, Schmidt LS, Shelley CS, Shen H, Shuch B, Signoretti S, Srinivasan R, Tamboli P, Thomas G, Vincent BG, Vocke CD, Wheeler DA, Yang L, Kim WY, Robertson AG; Cancer Genome Atlas Research Network, Spellman PT*,

- Rathmell WK***, Linehan WM*. The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. *Cell Rep.* 2018 Apr 3;23(1):313-326.e5. Erratum in: *Cell Rep.* 2018 Jun 19;23 (12):3698. PMID: 29617669 *Co-corresponding, ** Project co-leader.
28. Arreola A, Payne LB, Julian MH, de Cubas AA, Daniels AB, Taylor S, Zhao H, Darden J, Bautch VL, **Rathmell WK***, Chappell JC*. Von Hippel-Lindau mutations disrupt vascular patterning and maturation via Notch. *JCI Insight.* 2018 Feb 22;3(4). pii: 92193. PMID:29467323. *Co-corresponding author.
 29. Dronamraju R, Jha DK, Eser U, Adams AT, Dominguez D, Choudhury R, Chiang YC, **Rathmell WK**, Emanuele MJ, Churchman LS, Strahl BD. Set2 methyltransferase facilitates cell cycle progression by maintaining transcriptional fidelity. *Nucleic Acids Res.* 2018 Feb 16;46(3):1331-1344. PMID: 29294086
 30. Rojas JD, Lin F, Chiang YC, Chytil A, Chong DC, Bautch VL, **Rathmell WK**, Dayton PA. Ultrasound Molecular Imaging of VEGFR-2 in Clear-Cell Renal Cell Carcinoma Tracks Disease Response to Antiangiogenic and Notch-Inhibition Therapy. *Theranostics.* 2018 Jan 1;8(1):141-155. PMID:29290798
 31. Sun M, Tong P, Kong W, Dong B, Huang Y, Park IY, Zhou L, Liu XD, Ding Z, Zhang X, Bai S, German P, Powell R, Wang Q, Tong X, Tannir NM, Matin SF, **Rathmell WK**, Fuller GN, McCutcheon IE, Walker CL, Wang J, Jonasch E. HNF1B Loss Exacerbates the Development of Chromophobe Renal Cell Carcinomas. *Cancer Res.* 2017 Oct 1;77(19):5313-5326. Epub 2017 Aug 14. PMID: 28807937
 32. Chang EH, Chong WK, Kasoji SK, Fielding JR, Altun E, Mullin LB, Kim JI, Fine JP, Dayton PA, **Rathmell WK**. Diagnostic accuracy of contrast-enhanced ultrasound for characterization of kidney lesions in patients with and without chronic kidney disease. *BMC Nephrol.* 2017 Aug 9;18(1):266. PMID: 28793871
 33. Siska PJ, Beckermann KE, Mason FM, Andrejeva G, Greenplate AR, Sendor AB, Chiang YJ, Corona AL, Gemta LF, Vincent BG, Wang RC, Kim B, Hong J, Chen CL, Bullock TN, Irish JM, **Rathmell WK***, Rathmell JC*. Mitochondrial dysregulation and glycolytic insufficiency functionally impair CD8 T cells infiltrating human renal cell carcinoma. *JCI Insight.* 2017 Jun 15;2(12). [Epub ahead of print] PMID: 28614802 *Co-corresponding author.
 34. Siska PJ, Johnpulle RAN, Zhou A, Bordeaux J, Kim JY, Dabbas B, Dakappagari N, Rathmell JC, **Rathmell WK**, Morgans AK, Balko JM, Johnson DB.: Deep exploration of the immune infiltrate and outcome prediction in testicular cancer by quantitative multiplexed immunohistochemistry and gene expression profiling. *Oncoimmunology.* 2017 Mar 20;6(4) PMID: 28507813
 35. Yin Q, Hung SC, Wang L, Lin W, Fielding JR, **Rathmell WK**, Khandani AH, Woods ME, Milowsky MI, Brooks SA, Wallen EM, Shen D.: Associations between Tumor Vascularity, Vascular Endothelial Growth Factor Expression and PET/MRI Radiomic Signatures in Primary Clear-Cell-Renal-Cell-Carcinoma: Proof-of-Concept Study. *Sci Rep.* 2017 Mar 3;7:43356. PMID: 28256615
 36. Fishbein L, Leshchiner I, Walter V, Danilova L, Robertson AG, Johnson AR, Lichtenberg TM, Murray BA, Ghayee HK, Else T, Ling S, Jefferys SR, de Cubas AA, Wenz B, Korpershoek E, Amelio AL, Makowski L, **Rathmell WK**, Gimenez-Roqueplo AP, Giordano TJ, Asa SL, Tischler AS; Cancer Genome Atlas Research Network, Pacak K, Nathanson KL, Wilkerson MD.

- Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma. *Cancer Cell*. 2017 Feb 13;31(2):181-193. PMID: 28162975 (Analysis working group)
37. Nakajima, E, Leger, P, Mauer, IA, Neuss, MN, Chism, DD, **Rathmell, WK**. A case report of severe type B lactic acidosis following first dose of nivolumab in a VHL-mutated metastatic renal cell carcinoma. *Kidney Cancer*. 2017 1(1)
 38. Murakami A, Wang L, Kalhorn S, Schraml P, **Rathmell WK**, Tan AC, Nemenoff R, Stenmark K, Jiang BH, Reyland ME, Heasley L, Hu CJ. Context-dependent role for chromatin remodeling component PBRM1/BAF180 in clear cell renal cell carcinoma. *Oncogenesis*. 2017 Jan 16;6(1):e287. PMID: 28092369
 39. Kasoji SK, Chang EH, Mullin LB, Chong WK, **Rathmell WK**, Dayton PA. A Pilot Clinical Study in Characterization of Malignant Renal Cell Carcinoma Subtype with Contrast-Enhanced Ultrasound. *Ultrasound Imaging*. 2017 Mar;39(2):126-136. PMID: 27659687
 40. Beckermann KE, Jolly PC, Kim JY, Bordeaux J, Puzanov I, **Rathmell WK**, Johnson DB. Clinical and immunologic correlates of response to PD-1 blockade in a patient with metastatic renal medullary carcinoma. *J Immunother Cancer*. 2017 Jan 17;5:1. doi: 10.1186/s40425-016-0206-1. eCollection 2017. PMID: 28105368
 41. Park IY, Chowdhury P, Tripathi DN, Powell RT, Dere R, Terzo EA, **Rathmell WK**, Walker CL. Methylated α -tubulin antibodies recognize a new microtubule modification on mitotic microtubules. *MAbs*. 2016 Nov/Dec;8(8):1590-1597. PMID: 27594515
 42. de Velasco G, Miao D, Voss MH, Hakimi AA, Hsieh JJ, Tannir NM, Tamboli P, Appleman LJ, **Rathmell WK**, Van Allen EM, Choueiri TK. Tumor Mutational Load and Immune Parameters across Metastatic Renal Cell Carcinoma Risk Groups. *Cancer Immunol Res*. 2016 Oct;4(10):820-822. PMID: 27538576
 43. Hacker KE, Fahey CC, Shinsky SA, Chiang YJ, DiFiore JV, Jha DK, Vo AH, Shavit JA, Davis IJ, Strahl BD, **Rathmell WK**. Structure/Function Analysis of Recurrent Mutations in SETD2 Protein Reveals a Critical and Conserved Role for a SET Domain Residue in Maintaining Protein Stability and Histone H3 Lys-36 Trimethylation. *J Biol Chem*. 2016 Sep 30;291(40):21283-21295. PMID: 27528607
 44. Park IY, Powell RT, Tripathi DN, Dere R, Ho TH, Blasius TL, Chiang YC, Davis IJ, Fahey CC, Hacker KE, Verhey KJ, Bedford MT, Jonasch E, **Rathmell WK***, Walker CL*. Dual Chromatin and Cytoskeletal Remodeling by SETD2. *Cell*. 2016 Aug 11;166(4):950-62. PMID: 27518565
*Co-corresponding.
 45. Haake SM, Li J, Bai Y, Kinose F, Fang B, Welsh EA, Zent R, Dhillon J, Pow-Sang JM, Chen YA, Koomen JM, **Rathmell WK**, Fishman M, Haura EB. Tyrosine Kinase Signaling in Clear Cell and Papillary Renal Cell Carcinoma Revealed by Mass Spectrometry-Based Phosphotyrosine Proteomics. *Clin Cancer Res*. 2016 22(22):5605-5616. PMID: 27220961
 46. Kishon RJ, Barnes CE, Nichols AG, Cohen S, Gerriets VA, Siska PJ, Macintyre AN, Goraksha-Hicks P, de Cubas AA, Liu T, Warmoes MO, Abel ED, Yeoh AE, Gershon TR, **Rathmell WK**, Richards KL, Locasale JW, Rathmell JC. AMPK Is Essential to Balance Glycolysis and Mitochondrial Metabolism to Control T-ALL Cell Stress and Survival. *Cell Metab*. 2016 Apr 12;23(4):649-62. PMID: 27076078, PMCID: PMC4832577
 47. Brooks SA, Khandani A, Fielding J, Lin W, Sills T, Lee Y, Arreola A, Milowsky MI, Wallen EM, Woods ME, Smith AB, Nielsen ME, Parker JS, Lalush DS, **Rathmell WK**. Alternate metabolic

- programs define regional variation of relevant biological features in renal cell carcinoma progression. *Clin Cancer Res*. 2016 Jun 15;22(12):2950-9. PMID: 26787754
48. Haake SM, Brooks SA, Welsh E, Fulp WJ, Chen DT, Dhillon J, Haura E, Sexton W, Spiess PE, Pow-Sang J, **Rathmell WK**, Fishman M. Patients with ClearCode34-identified molecular subtypes of clear cell renal cell carcinoma represent unique populations with distinct comorbidities. *Urol Oncol*. 2016 Mar;34(3):122. PMID: 26546482 PMCID: PMC4761468
 49. Linehan WM, Spellman PT, Ricketts CJ, Creighton CJ, Fei SS, Davis C, Wheeler DA, Murray BA, Schmidt L, Vocke CD, Peto M, Al Mamun AA, Shinbrot E, Sethi A, Brooks S, **Rathmell WK**, Brooks AN, Hoadley KA, Robertson AG, Brooks D, Bowlby R, Sadeghi S, Shen H, Weisenberger DJ, Bootwalla M, Baylin SB, Laird PW, Cherniack AD, Saksena G, Haake S, Li J, Liang H, Lu Y, Mills GB, Akbani R, Leiserson MD, Raphael BJ, Anur P, Bottaro D, Albiges L, Barnabas N, Choueiri TK, Czerniak B, Godwin AK, Hakimi AA, Ho TH, Hsieh J, Ittmann M, Kim WY, Krishnan B, Merino MJ, Shaw KR, Reuter VE, Reznik E, Shelley CS, Shuch B, Signoretti S, Srinivasan R, Tamboli P, Thomas G, Tickoo S, Burnett K, Crain D, Gardner J, Lau K, Mallery D, Morris S, Paulauskis JD, Penny RJ, Shelton C, Shelton WT, Sherman M, Thompson E, Yena P, Avedon MT, Bowen J, Gastier-Foster JM, Gerken M, Leraas KM, Lichtenberg TM, Ramirez NC, Santos T, Wise L, Zmuda E, Demchok JA, Felau I, Hutter CM, Sheth M, Sofia HJ, Tarnuzzer R, Wang Z, Yang L, Zenklusen JC, Zhang J, Ayala B, Baboud J, Chudamani S, Liu J, Lolla L, Naresh R, Pihl T, Sun Q, Wan Y, Wu Y, Ally A, Balasundaram M, Balu S, Beroukhir R, Bodenheimer T, Buhay C, Butterfield YS, Carlsen R, Carter SL, Chao H, Chuah E, Clarke A, Covington KR, Dahdouli M, Dewal N, Dhalla N, Doddapaneni HV, Drummond JA, Gabriel SB, Gibbs RA, Guin R, Hale W, Hawes A, Hayes DN, Holt RA, Hoyle AP, Jefferys SR, Jones SJ, Jones CD, Kalra D, Kovar C, Lewis L, Li J, Ma Y, Marra MA, Mayo M, Meng S, Meyerson M, Mieczkowski PA, Moore RA, Morton D, Mose LE, Mungall AJ, Muzny D, Parker JS, Perou CM, Roach J, Schein JE, Schumacher SE, Shi Y, Simons JV, Sipahimalani P, Skelly T, Soloway MG, Sougnez C, Tam A, Tan D, Thiessen N, Veluvolu U, Wang M, Wilkerson MD, Wong T, Wu J, Xi L, Zhou J, Bedford J, Chen F, Fu Y, Gerstein M, Haussler D, Kasaian K, Lai P, Ling S, Radenbaugh A, Van Den Berg D, Weinstein JN, Zhu J, Albert M, Alexopoulou I, Andersen JJ, Auman JT, Bartlett J, Bastacky S, Bergsten J, Blute ML, Boice L, Bollag RJ, Boyd J, Castle E, Chen YB, Cheville JC, Curley E, Davies B, DeVolk A, Dhir R, Dike L, Eckman J, Engel J, Harr J, Hrebinko R, Huang M, Huelsenbeck-Dill L, Iacocca M, Jacobs B, Lobis M, Maranchie JK, McMeekin S, Myers J, Nelson J, Parfitt J, Parwani A, Petrelli N, Rabeno B, Roy S, Salner AL, Slaton J, Stanton M, Thompson RH, Thorne L, Tucker K, Weinberger PM, Winemiller C, Zach LA, Zuna R; Cancer Genome Atlas Research Network. Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. *N Engl J Med*. 2015 374(2):135-45 PMID: 26536169. **Analysis Working Group, Transcript Analysis Leader.
 50. Rose TL, Deal AM, Basch E, Godley PA, **Rathmell WK**, Kim WY, Whang YE, Dunn MW, Wang A, Chen RC, Nielsen ME, Pruthi RS, Wallen EM, Woods ME, Smith AB, Milowsky MI. Neoadjuvant chemotherapy administration and time to cystectomy for muscle-invasive bladder cancer: An evaluation of transitions between academic and community settings. *Urol Oncol*. 2015 33(9):38 PMID: 26122712
 51. Sendor AB, Hacker KE, Chen S, Corona AL, Sen O, Chiang DY, Snively A, Rogers AB, Montgomery SA, **Rathmell WK**, McRee AJ. Von Hippel-Lindau status influences phenotype of liver cancers arising from PTEN loss. *Gastrointest Cancer*. 2015 Feb 1;5:61-71. PMCID: PMC4383253

52. Rasmussen NR, Debebe Z, Wright TM, Brooks SA, Sendor AB, Brannon AR, Hakimi AA, Hsieh JJ, Choueiri TK, Tamboli P, Maranchie JK, Hinds P, Wallen EM, Simpson C, Norris JL, Janzen WP, **Rathmell WK**. Expression of Ror2 mediates invasive phenotypes in renal cell carcinoma. *PLoS One*. 2014 Dec 26;9(12):e116101. PMID: 25542006.
53. Begg CB, Seshan VE, Zabor EC, Furberg H, Arora A, Shen R, Maranchie JK, Nielsen ME, **Rathmell WK**, Signoretti S, Tamboli P, Karam JA, Choueiri TK, Hakimi AA, Hsieh JJ. Genomic investigation of etiologic heterogeneity: methodologic challenges. *BMC Med Res Methodol*. 2014 Dec 22;14(1):138. PMID: 25532962
54. Davis, CF*, Ricketts, C*, Wang, M*, Yang, L*, Cherniack, AD, Shen, H, Buhay, C, Kim, SC, Fahey, CC, Hacker, KE, Bhanot, G, Gordenin, DA, Chu, A, Gunaratne, PH, Biehl, M, Seth, S, Kaiparettu, BA, Bristow, CA, Donehower, LA, Wallen, EM, Smith, AB, Tickoo, SK, Tamboli, P, Reuter, V, Schmidt, LS, Hsieh, JJ, Choueiri, TK, Hakimi, AA, The Cancer Genome Atlas Research Network**, Chin, L, Meyerson, ML, Kucherlapati, R, Park, W-Y, Robertson, AG, Laird, PW, Henske, EP, Kwiatkowski, DJ, Park, PJ, Morgan, M, Shuch, B, Muzny, D, Wheeler, DA, Linehan, WM, Gibbs, RA, **Rathmell, WK****, Creighton, CJ**. The somatic genomic landscape of chromophobe renal cell carcinoma. *Cancer Cell*. 2014 26(3):319-330. PMCID PMC4160352. *Authors contributed equally to the work. **Project Leader, Transcript Analysis Team Leader, Co-corresponding author. Selected for cover.
55. Khandani AH, **Rathmell, WK**, Wallen EM, Ivanovic M. PET/CT with (124)I-cG250: great potential and some open questions. *AJR Am J Roentgenol*. 2014 Aug;203(2):261-2. PMID: 25055257
56. Brooks SA, Brannon AR, Parker JS, Fisher JC, Sen O, Kattan MW, Hakimi AA, Hsieh JJ, Choueiri TK, Tamboli P, Maranchie JK, Hinds P, Miller CR, Nielsen ME, **Rathmell, WK**. ClearCode34: A Prognostic Risk Predictor for Localized Clear Cell Renal Cell Carcinoma. *Eur Urol*. 2014 66(1):77-84 PMC4058355
57. Arreola, A, Cowey, CL, Coloff, J, Rathmell, JC, and **Rathmell, WK**. HIF1 and HIF2 exert differential preferences on nutrient utilization. *PLoS One*. 9(5):e98705. PMC4039535
58. Jagsi R, Spence R, **Rathmell WK**, Bradbury A, Peppercorn J, Grubbs S, Moy B. Ethical considerations for the clinical oncologist in an era of oncology drug shortages. *Oncologist*. 2014;19(2):186-92. PMCID: PMC3926786
59. Simon, J*, Hacker, KE*, Brannon, AR, Parker, JS, Weiser, M, Ho, TH, Kuan PF, Jonasch E, Furey TS, Prins JF, Lieb, JD**, **Rathmell, WK****, Davis, IJ.** Variation in chromatin accessibility in human kidney cancer links H3K36 methyltransferase loss with widespread RNA processing defects. *Genome Research*. 2014 24(2):241-50. PMCID: PMC3912414
60. **Cancer Genome Atlas Research Network**. Comprehensive molecular characterization of urothelial bladder carcinoma. *Nature*. 2014 507(7492):315-22. PMID: 24476821. *Collaborator, major contributor to analysis, Indexed as Kimryn Rathmell
61. Rasmussen, N, Wright, T, Debebe, Z, Hacker, KE, Sen, O, Major, MB, Green, J., Wahl, G, **Rathmell, WK**. Ror2 creates a poised signal for Wnt signaling in renal cell carcinoma. *J Biol Chemistry*, 288(36):26301-10, 2013. PMCID: PMC3764835
62. DeSimone, M, **Rathmell, WK***, Threadgill, D*, Pleiotropic Effects of the Trichloroethylene-Associated P81S VHL Mutation on Metabolism, Apoptosis and ATM-Mediated DNA Damage Response. *J. Natl. Cancer Inst*, 105(18):1355-64, 2013. PMCID: PMC3776265. Co-corresponding authors.

63. **The Cancer Genome Atlas Network.** Comprehensive molecular characterization of clear cell renal cell carcinoma. *Nature*, 499(7456):43-9, 2013. PMID:23792563. **Analysis Working Group, Transcriptional Analysis Lead, Clinical Data Lead, Lead Writing Team.
64. Olshan, AF, Kuo, T, Meyer, A-M, Nielsen, ME, Purdue, MP, and **Rathmell, WK.** Racial Difference in Histologic Subtype of Renal Cell Carcinoma. *Cancer Med.* 2013 Oct;2(5):744-9. PMCID: PMC3892806
65. Chen, J, Appelbaum, D, Kocherginsky, M, Cowey, CL, **Rathmell, WK**, McDermott, D, Stadler, W. FDG-PET as a Predictive Biomarker for Therapy with Everolimus in Metastatic Renal Cell Cancer (mRCC). *Cancer Med.* 2013 Aug;2(4):545-52. PMCID: PMC3799289
66. Lockhart AC, Brose MS, Kim ES, Johnson DH, Peppercorn JM, Michels DL, Storm CD, Schuchter LM, **Rathmell WK.** Physician and Stakeholder Perceptions of Conflict of Interest (COI) Policies in Oncology. *J Clin Oncol*, 31(13):1677-82, 2013. PMID: 23530092
67. Gameiro PA, Yang J, Metelo AM, Pérez-Carro R, Baker R, Wang Z, Arreola A, **Rathmell WK**, Olumi A, López-Larrubia P, Stephanopoulos G, Iliopoulos O. In vivo HIF-mediated reductive carboxylation is regulated by citrate levels and sensitizes VHL-deficient cells to glutamine deprivation. *Cell Metabolism.* 17(3):372-85, 2013. PMCID: PMC4003458
68. Gallagher SA, Smith AB, Matthews JE, Potter CW, Woods ME, Raynor M, Wallen EM, **Kimryn Rathmell W**, Whang YE, Kim WY, Godley PA, Chen RC, Wang A, You C, Barocas DA, Pruthi RS, Nielsen ME, Milowsky MI. Roadmap for the development of the University of North Carolina at Chapel Hill Genitourinary OncoLogy Database-UNC GOLD. *Urol Oncol.* 2014 Jan;32(1):32.e1-9 PMID: 23434424 *Indexed as Kimryn Rathmell, W.
69. Kapur P, Peña-Llopis S, Christie A, Zhrebker L, Pavía-Jiménez A, **Rathmell WK**, Xie XJ, Brugarolas J. Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation. *Lancet Oncol*, 14(2):159-167, 2013. PMID: 23333114
70. Valgus J, Singer EA, Berry S, **Rathmell WK.** Ethical Challenges: Managing Oncology Drug Shortages. *J Oncol Pract*, 9(2):e21-3, 2013. PMCID: PMC3595447
71. Stein A, Bellmunt J, Escudier B, Kim D, Stergiopoulos SG, Mietlowski W, Motzer RJ; RECORD-1 Trial Study Group. Survival prediction in everolimus-treated patients with metastatic renal cell carcinoma incorporating tumor burden response in the RECORD-1 trial. *Eur Urol.* 2013 Dec;64(6):994-1002. PMID: 23219086. Indexed as **K. Rathmell.**
72. Chen RC, Rosenman JG, Hoffman LG, Chiu WK, Wang AZ, Pruthi RS, Wallen EM, Crane JM, Kim WY, **Rathmell WK**, Godley PA, Whang YE Phase I study of concurrent weekly docetaxel, high-dose intensity-modulated radiation therapy (IMRT) and androgen-deprivation therapy (ADT) for high-risk prostate cancer. *BJU Int.* 2012 110(11 Pt B):E721-6. PMID: 23016517
73. Khandani, A, Cowey, CL, Moore, DT, Gohil, H, **Rathmell, WK.** Primary renal cell carcinoma: relationship between 18F-FDG uptake and response to neoadjuvant sorafenib. *Nuclear Medicine Communication*, 33(9):967-73, 2012. PMID: 22714005
74. Gamper, AM, Qiao, X, Kim, J, Zhang, L, DeSimone, MC, **Rathmell, WK**, Wan, Y. Regulation of KLF4 turnover reveals an unexpected tissue specific role of pVHL in tumorigenesis. *Molecular Cell*, 45(2):233-43, 2012. PMID: 22284679. PMCID: PMC3982234
75. Brannon, AR, Haake, SM, Hacker, KE, Pruthi, RS, Wallen, EM, Nielsen, ME, and **Rathmell, WK.** Meta-analysis of clear cell renal cell carcinoma gene expression defines a variant subgroup

- and identifies gender influences on tumor biology. *Eur Urol*. 2012 Feb;61(2):258-68. PMID: 22030119; PMC3244546
76. Manvar AM, **Rathmell WK**, Ferguson J, Pruthi RS, Nielsen ME, Wallen EM, Nolan N, Raynor MC. Carcinoma in a Cadaveric Transplant Kidney. *Urology*, 61(2):258-68, 2012. PMID: 22014593
 77. Teng BL, Hacker KE, Chen S, Means AR, **Rathmell WK**. Tumor Suppressive Activity of Prolyl Isomerase Pin1 in Renal Cell Carcinoma. *Mol Oncol*, Oct; 5(5):465-74, 2011. PMID: 21764651; PMC3194764 *Cover.
 78. Whang YE, Armstrong AJ, **Rathmell WK**, Godley PA, Kim WY, Pruthi RS, Wallen EM, Crane JM, Moore DT, Grigson G, Morris K, Watkins CP, George DJ. A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer. *Urol Oncol*. 31(1):82-6, 2013. PMID: 21470103
 79. Brannon, AR *, Reddy, A.*, Seiler, M., Arreola, A., Moore, D.T., Pruthi, R., Wallen, E., Liu, H., Ljungberg, B, Zhao, H, Brooks, JD, Ganesan, S, Bhanot, G, and **Rathmell, WK**. Molecular Stratification of Clear Cell Renal Cell Carcinoma Reveals Distinct Subtypes and Survival Patterns. *Co-first authorship. *Genes and Cancer*, 1(2): 152-163, 2010. PMID: 20871783; PMC2943630
 80. Bender, AA, Tang, W, Middeldorp, JM, Greijer, AE, Thorne, LB, Funkhouser, WK, **Rathmell, WK**, Gulley, MA Epstein-Barr Virus Latent Membrane Protein 1 is not Associated with Vessel Density nor with Hypoxia Inducible Factor 1 Alpha Expression in Nasopharyngeal Carcinoma Tissue. *Head and Neck Pathology*. 3(4):276-82. 2010. PMID: 20871783
 81. Liu, H, Brannon, AR, Reddy, A, Alexe, G, Seiler, M, Arreola, A, Oza, J, Yao, M, Juan, D, Liou, L, Ganesan, S, Levine, AJ, **Rathmell, WK***, Bhanot, G*, Identifying direct mRNA targets of microRNA in clear cell renal cell carcinoma. *BMC Systems Biology*, 4(1):51, 2010. *Co-corresponding authors. PMID: 20420713; PMC2876063
 82. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N, Kay A, Ravaud A; RECORD-1 Study Group. Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. *Cancer*. 116(18):4256-65, 2010. PMID: 20549832. * Indexed as **K. Rathmell**.
 83. Chen, S, Sanford, CA, Sun, J, Choi, V, Van Dyke, T, Samulski, RJ, and **Rathmell, WK**. VHL and PTEN loss coordinate to promote liver vascular lesions. *Angiogenesis*, 13(1): 59-69, 2010. PMID: 20221685
 84. Wright, TM, **Rathmell, WK**. Identification of Ror2 as a hypoxia inducible factor (HIF) target in von Hippel-Lindau (VHL)-associated renal cell carcinoma. *J Biol Chemistry*. 285(17):12916-24, 2010. PMID: 20185829; PMC2857057
 85. Cowey, CL, Amin, C, Pruthi, RS, Wallen, EM, Nielsen, ME, Grigson, G, Watkins, C, Nance, KV, Crane, J, Jalkut, M, Kim, WY, Godley, PA, Whang, YE, Fielding, JR, and **Rathmell, WK**. A Neoadjuvant Clinical Trial with Sorafenib for Patients with Stage II or Greater Renal Cell Carcinoma. *J. Clin. Oncol.*, 28(9): 1502-7, 2010. PMID: 20159822
 86. Pruthi, RS, Nielsen, M, Heathcote, S, Wallen, EM, **Rathmell, WK**, Godley, P, Whang, Y, Fielding, J, Schultz, H, Grigson, G, Smith, A, Kim, WY. A phase II trial of neoadjuvant erlotinib in patients with muscle-invasive bladder cancer undergoing radical cystectomy: clinical and pathological results. *BJU Int*, 106(3):349-56, 2010. 20089114

87. Kim WY, Whang YE, Pruthi RS, Baggstrom MQ, **Rathmell WK**, Rosenman JG, Wallen EM, Goyal LK, Grigson G, Watkins C, Godley PA. Neoadjuvant docetaxel/ estramustine prior to radical prostatectomy or external beam radiotherapy in high risk localized prostate cancer: A phase II trial. *Urol. Oncol*, 29(6):608-13, 2011. PMID: 20022268
88. Cowey, CL, Fielding, J, and **Rathmell, WK**. The Loss of Radiographic Enhancement in Primary Renal Cell Carcinoma Tumors Following Multi-targeted Receptor Tyrosine Kinase Therapy is an Additional Indicator of Response. *Urology*, 75(5):1108-13.e1, 2010. PMID: 19931124
89. Kurpad, R, Kim, WY, **Rathmell, WK**, Godley, P, Whang, Y, Fielding, J, Smith, L, Pettiford, A, Schultz, H, Nielsen, ME, Wallen, EM, Pruthi, RS. A multidisciplinary approach to the management of urologic malignancies: Does it influence diagnostic and treatment decisions? *Urol. Oncol*, 29(4):378-82, 2011. PMID: 19576797
90. Wright, TM, Brannon, AR, Gordan, JD, Mikels, AJ, Mitchell, C, Chen, S, Espinosa, I, van de Rijn, M, Pruthi, RS, Wallen, E, Edwards, L, Nusse, R, and **Rathmell, WK**. Ror2, a developmentally regulated kinase, promotes tumor growth potential in renal cell carcinoma. *Oncogene*, 28: 2513-2523, 2009. PMID: 19448672; PMC2771692
91. Lee, CM, Hickey, MM, Sanford, CA, McGuire, CG, Cowey, CL, Simon, MC, and **Rathmell, WK**. VHL Type 2B gene mutation moderates HIF dosage in vitro and in vivo. *Oncogene*, 2009, 28: 1694-1705. PMID: 19252526; PMC2667565
92. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A; RECORD-1 Study Group. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. *Lancet*, 372(9637):449-56, 2008. PMID:18653228. *Indexed as **K. Rathmell**.
93. **Rathmell, WK** and Monk, JP. High-dose-intensity MVAC for Advanced Renal Medullary Carcinoma: Report of Three Cases and Literature Review. *Urology*, 72: 659-663, 2008. PMID: 18649931
94. Hacker, KE, Lee, CM, and **Rathmell, WK**. VHL type 2B mutations retain VBC complex form and function. *PLoS One*, 3: e3801, 2008. PMID: 19030229; PMC2583047
95. Gordan, JD, Lal, P, Dondeti, VR, Letrero, R, Parekh, KN, Oquendo, CE, Greenberg, RA, Flaherty, KT, **Rathmell, WK**, Keith, B, Simon, MC, and Nathanson, KL. HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. *Cancer Cell*, 14: 435-446, 2008. PMID: 19061835; PMC2621440
96. Amin, C, Wallen, E, Pruthi, RS, Calvo, BF, Godley, PA, and **Rathmell, WK**. Preoperative tyrosine kinase inhibition as an adjunct to debulking nephrectomy. *Urology*, 72: 864-868, 2008. PMID: 18684493
97. Hickey, MM, Lam, JC, Bezman, NA, **Rathmell, WK**, and Simon, MC. von Hippel-Lindau mutation in mice recapitulates Chuvash polycythemia via hypoxia-inducible factor-2alpha signaling and splenic erythropoiesis. *J Clin Invest*, 117: 3879-3889, 2007. PMID: 17992257
98. Gollob, JA, **Rathmell, WK**, Richmond, TM, Marino, CB, Miller, EK, Grigson, G, Watkins, C, Gu, L, Peterson, BL, and Wright, JJ. Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer. *J Clin Oncol*, 25: 3288-3295, 2007. PMID: 17664476

99. **Rathmell, WK**, Malkowicz, SB, Holroyde, C, Luginbuhl, W, and Vaughn, DJ. Phase II trial of 5-fluorouracil and leucovorin in combination with interferon-alpha and interleukin-2 for advanced renal cell cancer. *Am J Clin Oncol*, 27: 109-112, 2004. PMID: 15057147
100. **Rathmell, WK**, Hickey, MM, Bezman, NA, Chmielecki, CA, Carraway, NC, and Simon, MC. In vitro and in vivo models analyzing von Hippel-Lindau disease-specific mutations. *Cancer Res*, 64: 8595-8603, 2004. PMID: 15574766
101. **Rathmell, WK**, Acs, G, Simon, MC, and Vaughn, DJ. HIF transcription factor expression and induction of hypoxic response genes in a retroperitoneal angiosarcoma. *Anticancer Res*, 24: 167-169, 2004. PMID: 15015593
102. Mack, FA, **Rathmell, WK**, Arsham, AM, Gnarra, J, Keith, B, and Simon, MC. Loss of pVHL is sufficient to cause HIF dysregulation in primary cells but does not promote tumor growth. *Cancer Cell*, 3: 75-88, 2003. PMID: 12559177
103. **Rathmell, WK**, Arguin, P, Chan, S, and Yu, A. Yersinia pseudotuberculosis bacteremia and splenic abscess in a patient with non-insulin-dependent diabetes mellitus. *West J Med*, 170: 110-112, 1999. PMID: 10063398
104. Smider, VV, **Rathmell, WK**, Brown, G, Lewis, S, and Chu, G. Failure of hairpin-ended and nicked DNA to activate DNA-dependent protein kinase: implications for V(D)J recombination. *Mol Cell Biol*, 18: 6853-6858, 1998. PMID: 9774698
105. **Rathmell, WK**, Kaufmann, WK, Hurt, JC, Byrd, LL, and Chu, G. DNA-dependent protein kinase is not required for accumulation of p53 or cell cycle arrest after DNA damage. *Cancer Res*, 57: 68-74, 1997. PMID: 8988043
106. Errami, A, Smider, VV, **Rathmell, WK**, He, DM, Hendrickson, EA, Zdzienicka, MZ, and Chu, G. Ku86 defines the genetic defect and restores X-ray resistance and V(D)J recombination to complementation group 5 hamster cell mutants. *Mol Cell Biol*, 16: 1519-1526, 1996. PMID: 8657125
107. Smider, VV*, **Rathmell, WK***, Lieber, MR, and Chu, G. Restoration of X-ray resistance and V(D)J recombination in mutant cells by Ku cDNA. *Science*, 266: 288-291, 1994. PMID: 7939667
*Co-first authorship.
108. **Rathmell, WK** and Chu, G. A DNA end-binding factor involved in double-strand break repair and V(D)J recombination. *Mol Cell Biol*, 14: 4741-4748, 1994. PMID: 7516471
109. **Rathmell, WK** and Chu, G. Involvement of the Ku autoantigen in the cellular response to DNA double-strand breaks. *Proc Natl Acad Sci U S A*, 91: 7623-7627, 1994. PMID: 8052631
110. Wiens, DJ, Mann, TK, Feddersen, DE, **Rathmell, WK**, and Franck, BH Early heart development in the chick embryo: effects of isotretinoin on cell proliferation, alpha-actin synthesis, and development of contractions. *Differentiation*, 51: 105-112, 1992. PMID: 1473624

Consortium Manuscripts (peer reviewed)

1. Bailey MH, Meyerson WU, Dursi LJ, Wang LB, Dong G, Liang WW, Weerasinghe A, Li S, Li Y, Kelso S; MC3 Working Group; PCAWG novel somatic mutation calling methods working group, Saksena G, Ellrott K, Wendl MC, Wheeler DA, Getz G, Simpson JT, Gerstein MB, Ding L; **PCAWG Consortium**. Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples. *Nat Commun*. 2020 Sep 21;11(1):4748.

doi: 10.1038/s41467-020-18151-y. Erratum in: *Nat Commun*. 2020 Nov 30;11(1):6232. PMID: 32958763; PMCID: PMC7505971.

2. Li CH, Prokopec SD, Sun RX, Yousif F, Schmitz N; PCAWG Tumour Subtypes and Clinical Translation, Boutros PC; **PCAWG Consortium**. Sex differences in oncogenic mutational processes. *Nat Commun*. 2020 Aug 28;11(1):4330. doi: 10.1038/s41467-020-17359-2. PMID: 32859912; PMCID: PMC7455744.
3. ICGC/**TCGA Pan-Cancer Analysis of Whole Genomes Consortium**. Pan-cancer analysis of whole genomes. *Nature*. 2020 Feb;578(7793):82-93. doi: 10.1038/s41586-020-1969-6. Epub 2020 Feb 5. PMID: 32025007; PMCID: PMC7025898.
4. Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, Porta-Pardo E, Gao GF, Plaisier CL, Eddy JA, Ziv E, Culhane AC, Paull EO, Sivakumar IKA, Gentles AJ, Malhotra R, Farshidfar F, Colaprico A, Parker JS, Mose LE, Vo NS, Liu J, Liu Y, Rader J, Dhankani V, Reynolds SM, Bowlby R, Califano A, Cherniack AD, Anastassiou D, Bedognetti D, Mokrab Y, Newman AM, Rao A, Chen K, Krasnitz A, Hu H, Malta TM, Noushmehr H, Pedamallu CS, Bullman S, Ojesina AI, Lamb A, Zhou W, Shen H, Choueiri TK, Weinstein JN, Guinney J, Saltz J, Holt RA, Rabkin CS; **Cancer Genome Atlas Research Network**, Lazar AJ, Serody JS, Demicco EG, Disis ML, Vincent BG, Shmulevich I. The Immune Landscape of Cancer. *Immunity*. 2019 Aug 20;51(2):411-412. PMID: 31433971
5. Korkut A, Zaidi S, Kanchi RS, Rao S, Gough NR, Schultz A, Li X, Lorenzi PL, Berger AC, Robertson G, Kwong LN, Datto M, Roszik J, Ling S, Ravikumar V, Manyam G, Rao A, Shelley S, Liu Y, Ju Z, Hansel D, de Velasco G, Pennathur A, Andersen JB, O'Rourke CJ, Ohshiro K, Jogunoori W, Nguyen BN, Li S, Osmanbeyoglu HU, Ajani JA, Mani SA, Houseman A, Wiznerowicz M, Chen J, Gu S, Ma W, Zhang J, Tong P, Cherniack AD, Deng C, Resar L; **Cancer Genome Atlas Research Network**, Weinstein JN, Mishra L, Akbani R. A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF- β Superfamily. *Cell Syst*. 2018 Oct 24;7(4):422-437.e7 PMID: 30268436
6. Wang Y, Xu X, Maglic D, Dill MT, Mojumdar K, Ng PK, Jeong KJ, Tsang YH, Moreno D, Bhavana VH, Peng X, Ge Z, Chen H, Li J, Chen Z, Zhang H, Han L, Du D, Creighton CJ, Mills GB; **Cancer Genome Atlas Research Network**, Camargo F, Liang H. Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer. *Cell Rep*. 2018 Oct 30;25(5):1304-1317.e5.
7. Korkut A, Zaidi S, Kanchi RS, Rao S, Gough NR, Schultz A, Li X, Lorenzi PL, Berger AC, Robertson G, Kwong LN, Datto M, Roszik J, Ling S, Ravikumar V, Manyam G, Rao A, Shelley S, Liu Y, Ju Z, Hansel D, de Velasco G, Pennathur A, Andersen JB, O'Rourke CJ, Ohshiro K, Jogunoori W, Nguyen BN, Li S, Osmanbeyoglu HU, Ajani JA, Mani SA, Houseman A, Wiznerowicz M, Chen J, Gu S, Ma W, Zhang J, Tong P, Cherniack AD, Deng C, Resar L; **Cancer Genome Atlas Research Network**, Weinstein JN, Mishra L, Akbani R. A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF- β Superfamily. *Cell Syst*. 2018 Sep 14. PMID: 30268436
8. Bailey MH, Tokheim C, Porta-Pardo E, Sengupta S, Bertrand D, Weerasinghe A, Colaprico A, Wendl MC, Kim J, Reardon B, Kwok-Shing Ng P, Jeong KJ, Cao S, Wang Z, Gao J, Gao Q, Wang F, Liu EM, Mularoni L, Rubio-Perez C, Nagarajan N, Cortés-Ciriano I, Zhou DC, Liang WW, Hess JM, Yellapantula VD, Tamborero D, Gonzalez-Perez A, Suphavitai C, Ko

- JY, Khurana E, Park PJ, Van Allen EM, Liang H; MC3 Working Group; **Cancer Genome Atlas Research Network**, Lawrence MS, Godzik A, Lopez-Bigas N, Stuart J, Wheeler D, Getz G, Chen K, Lazar AJ, Mills GB, Karchin R, Ding L. Comprehensive Characterization of Cancer Driver Genes and Mutations. *Cell*. 2018 Aug 9;174(4):1034-1035. PMID: 30096302
9. Kahles A, Lehmann KV, Toussaint NC, Hüser M, Stark SG, Sachsenberg T, Stegle O, Kohlbacher O, Sander C; **Cancer Genome Atlas Research Network**, Rättsch G. Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients. *Cancer Cell*. 2018 Aug 13;34(2):211-224.e6. PMID: 30078747
 10. Shen H, Shih J, Hollern DP, Wang L, Bowlby R, Tickoo SK, Thorsson V, Mungall AJ, Newton Y, Hegde AM, Armenia J, Sánchez-Vega F, Pluta J, Pyle LC, Mehra R, Reuter VE, Godoy G, Jones J, Shelley CS, Feldman DR, Vidal DO, Lessel D, Kulis T, Cárcano FM, Leraas KM, Lichtenberg TM, Brooks D, Cherniack AD, Cho J, Heiman DI, Kasaian K, Liu M, Noble MS, Xi L, Zhang H, Zhou W, Zenklusen JC, Hutter CM, Felau I, Zhang J, Schultz N, Getz G, Meyerson M, Stuart JM; **Cancer Genome Atlas Research Network**, Akbani R, Wheeler DA, Laird PW, Nathanson KL, Cortessis VK, Hoadley KA. Integrated Molecular Characterization of Testicular Germ Cell Tumors. *Cell Rep*. 2018 Jun 12;23(11):3392-3406. PMID: 29898407
 11. Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, Porta-Pardo E, Gao GF, Plaisier CL, Eddy JA, Ziv E, Culhane AC, Paull EO, Sivakumar IKA, Gentles AJ, Malhotra R, Farshidfar F, Colaprico A, Parker JS, Mose LE, Vo NS, Liu J, Liu Y, Rader J, Dhankani V, Reynolds SM, Bowlby R, Califano A, Cherniack AD, Anastassiou D, Bedognetti D, Rao A, Chen K, Krasnitz A, Hu H, Malta TM, Noushmehr H, Peadamallu CS, Bullman S, Ojesina AI, Lamb A, Zhou W, Shen H, Choueiri TK, Weinstein JN, Guinney J, Saltz J, Holt RA, Rabkin CE; **Cancer Genome Atlas Research Network**, Lazar AJ, Serody JS, Demicco EG, Disis ML, Vincent BG, Shmulevich L. The Immune Landscape of Cancer. *Immunity*. 2018 Apr 17;48(4):812-830.e14. PMID: 29628290
 12. Liu J, Lichtenberg T, Hoadley KA, Poisson LM, Lazar AJ, Cherniack AD, Kovatich AJ, Benz CC, Levine DA, Lee AV, Omberg L, Wolf DM, Shriver CD, Thorsson V; **Cancer Genome Atlas Research Network**, Hu H. An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. *Cell*. 2018 Apr 5;173(2):400-416.e11.
 13. Chen H, Li C, Peng X, Zhou Z, Weinstein JN; **Cancer Genome Atlas Research Network**, Liang H. A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples. *Cell*. 2018 Apr 5;173(2):386-399.e12. PMID: 29625054
 14. Bailey MH, Tokheim C, Porta-Pardo E, Sengupta S, Bertrand D, Weerasinghe A, Colaprico A, Wendl MC, Kim J, Reardon B, Ng PK, Jeong KJ, Cao S, Wang Z, Gao J, Gao Q, Wang F, Liu EM, Mularoni L, Rubio-Perez C, Nagarajan N, Cortés-Ciriano I, Zhou DC, Liang WW, Hess JM, Yellapantula VD, Tamborero D, Gonzalez-Perez A, Suphavilai C, Ko JY, Khurana E, Park PJ, Van Allen EM, Liang H; MC3 Working Group; **Cancer Genome Atlas Research Network**, Lawrence MS, Godzik A, Lopez-Bigas N, Stuart J, Wheeler D, Getz G, Chen K, Lazar AJ, Mills GB, Karchin R, Ding L. Comprehensive Characterization of Cancer Driver Genes and Mutations. *Cell*. 2018 Apr 5;173(2):371-385.e18. PMID: 29625053
 15. Huang KL, Mashl RJ, Wu Y, Ritter DI, Wang J, Oh C, Paczkowska M, Reynolds S, Wyczalkowski MA, Oak N, Scott AD, Krassowski M, Cherniack AD, Houlahan KE,

- Jayasinghe R, Wang LB, Zhou DC, Liu D, Cao S, Kim YW, Koire A, McMichael JF, Huchtagowder V, Kim TB, Hahn A, Wang C, McLellan MD, Al-Mulla F, Johnson KJ; **Cancer Genome Atlas Research Network**, Lichtarge O, Boutros PC, Raphael B, Lazar AJ, Zhang W, Wendl MC, Govindan R, Jain S, Wheeler D, Kulkarni S, Dipersio JF, Reimand J, Meric-Bernstam F, Chen K, Shmulevich I, Plon SE, Chen F, Ding L. Pathogenic Germline Variants in 10,389 Adult Cancers. *Cell*. 2018 Apr 5;173(2):355-370.e14. PMID: 29625052
16. Malta TM, Sokolov A, Gentles AJ, Burzykowski T, Poisson L, Weinstein JN, Kamińska B, Huelsken J, Omberg L, Gevaert O, Colaprico A, Czerwińska P, Mazurek S, Mishra L, Heyn H, Krasnitz A, Godwin AK, Lazar AJ; **Cancer Genome Atlas Research Network**, Stuart JM, Hoadley KA, Laird PW, Noushmehr H, Wiznerowicz M. Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. *Cell*. 2018 Apr 5;173(2):338-354.e15. PMID:29625051
17. Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC, Dimitriadoy S, Liu DL, Kantheti HS, Saghafeinia S, Chakravarty D, Daian F, Gao Q, Bailey MH, Liang WW, Foltz SM, Shmulevich I, Ding L, Heins Z, Ochoa A, Gross B, Gao J, Zhang H, Kundra R, Kandath C, Bahceci I, Dervishi L, Dogrusoz U, Zhou W, Shen H, Laird PW, Way GP, Greene CS, Liang H, Xiao Y, Wang C, Iavarone A, Berger AH, Bivona TG, Lazar AJ, Hammer GD, Giordano T, Kwong LN, McArthur G, Huang C, Tward AD, Frederick MJ, McCormick F, Meyerson M; **Cancer Genome Atlas Research Network**, Van Allen EM, Cherniack AD, Ciriello G, Sander C, Schultz N. Oncogenic Signaling Pathways in The Cancer Genome Atlas. *Cell*. 2018 Apr 5;173(2):321-337.e10. PMID: 29625050
18. Hoadley KA, Yau C, Hinoue T, Wolf DM, Lazar AJ, Drill E, Shen R, Taylor AM, Cherniack AD, Thorsson V, Akbani R, Bowlby R, Wong CK, Wiznerowicz M, Sanchez-Vega F, Robertson AG, Schneider BG, Lawrence MS, Noushmehr H, Malta TM; **Cancer Genome Atlas Network**, Stuart JM, Benz CC, Laird PW. Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer. *Cell*. 2018 Apr 5;173(2):291-304.e6. PMID:29625048
19. Liu Y, Sethi NS, Hinoue T, Schneider BG, Cherniack AD, Sanchez-Vega F, Seoane JA, Farshidfar F, Bowlby R, Islam M, Kim J, Chatila W, Akbani R, Kanchi RS, Rabkin CS, Willis JE, Wang KK, McCall SJ, Mishra L, Ojesina AI, Bullman S, Pedamallu CS, Lazar AJ, Sakai R; **Cancer Genome Atlas Research Network**, Thorsson V, Bass AJ, Laird PW. Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas. *Cancer Cell*. 2018 Apr 9;33(4):721-735.e8 PMID:29622466
20. Wang Z, Yang B, Zhang M, Guo W, Wu Z, Wang Y, Jia L, Li S; **Cancer Genome Atlas Research Network**, Xie W, Yang D. lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer. *Cancer Cell*. 2018 Apr 9;33(4):706-720.e9. PMID: 29622465
21. Berger AC, Korkut A, Kanchi RS, Hegde AM, Lenoir W, Liu W, Liu Y, Fan H, Shen H, Ravikumar V, Rao A, Schultz A, Li X, Sumazin P, Williams C, Mestdagh P, Gunaratne PH, Yau C, Bowlby R, Robertson AG, Tiezzi DG, Wang C, Cherniack AD, Godwin AK, Kuderer NM, Rader JS, Zuna RE, Sood AK, Lazar AJ, Ojesina AI, Adebamowo C, Adebamowo SN, Baggerly KA, Chen TW, Chiu HS, Lefever S, Liu L, MacKenzie K, Orsulic S, Roszik J, Shelley CS, Song Q, Vellano CP, Wentzensen N; **Cancer Genome Atlas Research Network**, Weinstein JN, Mills GB, Levine DA, Akbani R. A Comprehensive Pan-Cancer Molecular

- Study of Gynecologic and Breast Cancers. *Cancer Cell*. 2018 Apr 9;33(4):690-705.e9. PMID:29622464
22. Taylor AM, Shih J, Ha G, Gao GF, Zhang X, Berger AC, Schumacher SE, Wang C, Hu H, Liu J, Lazar AJ; **Cancer Genome Atlas Research Network**, Cherniack AD, Beroukhim R, Meyerson M. Genomic and Functional Approaches to Understanding Cancer Aneuploidy. *Cancer Cell*. 2018 Apr 9;33(4):676-689.e3. PMID:29622463
 23. Chiu HS, Somvanshi S, Patel E, Chen TW, Singh VP, Zorman B, Patil SL, Pan Y, Chatterjee SS; **Cancer Genome Atlas Research Network**, Sood AK, Gunaratne PH, Sumazin P. Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context. *Cell Rep*. 2018 Apr 3;23(1):297-312.e12. PMID: 29617668
 24. Seiler M, Peng S, Agrawal AA, Palacino J, Teng T, Zhu P, Smith PG; **Cancer Genome Atlas Research Network**, Buonamici S, Yu L. Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types. *Cell Rep*. 2018 Apr 3;23(1):282-296.e4. PMID:29617667
 25. Jayasinghe RG, Cao S, Gao Q, Wendl MC, Vo NS, Reynolds SM, Zhao Y, Climente-González H, Chai S, Wang F, Varghese R, Huang M, Liang WW, Wyczalkowski MA, Sengupta S, Li Z, Payne SH, Fenyö D, Miner JH, Walter MJ; **Cancer Genome Atlas Research Network**, Vincent B, Eyras E, Chen K, Shmulevich I, Chen F, Ding L. Systematic Analysis of Splice-Site-Creating Mutations in Cancer. *Cell Rep*. 2018 Apr 3;23(1):270-281.e3. PMID:29617666
 26. Peng X, Chen Z, Farshidfar F, Xu X, Lorenzi PL, Wang Y, Cheng F, Tan L, Mojumdar K, Du D, Ge Z, Li J, Thomas GV, Birsoy K, Liu L, Zhang H, Zhao Z, Marchand C, Weinstein JN; **Cancer Genome Atlas Research Network**, Bathe OF, Liang H. Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers. *Cell Rep*. 2018 Apr 3;23(1):255-269.e4. PMID: 29617665
 27. Knijnenburg TA, Wang L, Zimmermann MT, Chambwe N, Gao GF, Cherniack AD, Fan H, Shen H, Way GP, Greene CS, Liu Y, Akbani R, Feng B, Donehower LA, Miller C, Shen Y, Karimi M, Chen H, Kim P, Jia P, Shinbrot E, Zhang S, Liu J, Hu H, Bailey MH, Yau C, Wolf D, Zhao Z, Weinstein JN, Li L, Ding L, Mills GB, Laird PW, Wheeler DA, Shmulevich I; **Cancer Genome Atlas Research Network**, Monnat RJ Jr, Xiao Y, Wang C. Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas. *Cell Rep*. 2018 Apr 3;23(1):239-254.e6. PMID:29617664
 28. Gao Q, Liang WW, Foltz SM, Mutharasu G, Jayasinghe RG, Cao S, Liao WW, Reynolds SM, Wyczalkowski MA, Yao L, Yu L, Sun SQ; Fusion Analysis Working Group; **Cancer Genome Atlas Research Network**, Chen K, Lazar AJ, Fields RC, Wendl MC, Van Tine BA, Vij R, Chen F, Nykter M, Shmulevich I, Ding L. Driver Fusions and Their Implications in the Development and Treatment of Human Cancers. *Cell Rep*. 2018 Apr 3;23(1):227-238.e3. PMID:29617662
 29. Ge Z, Leighton JS, Wang Y, Peng X, Chen Z, Chen H, Sun Y, Yao F, Li J, Zhang H, Liu J, Shriver CD, Hu H; **Cancer Genome Atlas Research Network**, Piwnicka-Worms H, Ma L, Liang H. Integrated Genomic Analysis of the Ubiquitin Pathway across Cancer Types. *Cell Rep*. 2018 Apr 3;23(1):213-226.e3. PMID:29617661
 30. Campbell JD, Yau C, Bowlby R, Liu Y, Brennan K, Fan H, Taylor AM, Wang C, Walter V, Akbani R, Byers LA, Creighton CJ, Coarfa C, Shih J, Cherniack AD, Gevaert O, Prunello M,

- Shen H, Anur P, Chen J, Cheng H, Hayes DN, Bullman S, Pedamallu CS, Ojesina AI, Sadeghi S, Mungall KL, Robertson AG, Benz C, Schultz A, Kanchi RS, Gay CM, Hegde A, Diao L, Wang J, Ma W, Sumazin P, Chiu HS, Chen TW, Gunaratne P, Donehower L, Rader JS, Zuna R, Al-Ahmadie H, Lazar AJ, Flores ER, Tsai KY, Zhou JH, Rustgi AK, Drill E, Shen R, Wong CK; **Cancer Genome Atlas Research Network**, Stuart JM, Laird PW, Hoadley KA, Weinstein JN, Peto M, Pickering CR, Chen Z, Van Waes C. Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas. *Cell Rep*. 2018 Apr 3;23(1):194-212.e6. PMID:29617660
31. Saltz J, Gupta R, Hou L, Kurc T, Singh P, Nguyen V, Samarasinghe D, Shroyer KR, Zhao T, Batiste R, Van Arnam J; **Cancer Genome Atlas Research Network**, Shmulevich I, Rao AUK, Lazar AJ, Sharma A, Thorsson V. Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images. *Cell Rep*. 2018 Apr 3;23(1):181-193.e7. PMID:29617659
 32. Way GP, Sanchez-Vega F, La K, Armenia J, Chatila WK, Luna A, Sander C, Cherniack AD, Mina M, Ciriello G, Schultz N; **Cancer Genome Atlas Research Network**, Sanchez Y, Greene CS. Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas. *Cell Rep*. 2018 Apr 3;23(1):172-180.e3. PMID:29617658
 33. Schaub FX, Dhankani V, Berger AC, Trivedi M, Richardson AB, Shaw R, Zhao W, Zhang X, Ventura A, Liu Y, Ayer DE, Hurlin PJ, Cherniack AD, Eisenman RN, Bernard B, Grandori C; **Cancer Genome Atlas Network**. Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas. *Cell Syst*. 2018 Mar 28;6(3):282-300.e2. PMID:29596783
 34. Ellrott K, Bailey MH, Saksena G, Covington KR, Kandoth C, Stewart C, Hess J, Ma S, Chiotti KE, McLellan M, Sofia HJ, Hutter C, Getz G, Wheeler D, Ding L; MC3 Working Group; **Cancer Genome Atlas Research Network**. Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines. *Cell Syst*. 2018 Mar 28;6(3):271-281.e7. PMID:29596782
 35. **Cancer Genome Atlas Research Network**. Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas. *Cell*. 2017 Nov 2;171(4):950-965.e28. PMID: 29100075
 36. Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, Hinoue T, Laird PW, Hoadley KA, Akbani R, Castro MAA, Gibb EA, Kanchi RS, Gordenin DA, Shukla SA, Sanchez-Vega F, Hansel DE, Czerniak BA, Reuter VE, Su X, de Sa Carvalho B, Chagas VS, Mungall KL, Sadeghi S, Pedamallu CS, Lu Y, Klimczak LJ, Zhang J, Choo C, Ojesina AI, Bullman S, Leraas KM, Lichtenberg TM, Wu CJ, Schultz N, Getz G, Meyerson M, Mills GB, McConkey DJ; **TCGA Research Network**, Weinstein JN, Kwiatkowski DJ, Lerner SP. Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. *Cell*. 2017 Oct 19;171(3):540-556.e25. PMID: 28988769
 37. **Cancer Genome Atlas Research Network**. Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. *Cancer Cell*. 2017 Aug 14;32(2):185-203.e13. PMID: 28810144
 38. **Cancer Genome Atlas Research Network**. Integrated genomic and molecular characterization of cervical cancer. *Nature*. 2017 Mar 16;543(7645):378-384. PMID: 28112728

39. **Cancer Genome Atlas Research Network** Integrated genomic characterization of oesophageal carcinoma. *Nature*. 2017 2017 Jan 12;541(7636):169-175. PMID:28052061
40. Farshidfar F, Zheng S, Gingras MC, Newton Y, Shih J, Robertson AG, Hinoue T, Hoadley KA, Gibb EA, Roszik J, Covington KR, Wu CC, Shinbrot E, Stransky N, Hegde A, Yang JD, Reznik E, Sadeghi S, Pedamallu CS, Ojesina AI, Hess JM, Auman JT, Rhie SK, Bowlby R, Borad MJ; **Cancer Genome Atlas Network**, Zhu AX, Stuart JM, Sander C, Akbani R, Cherniack AD, Deshpande V, Mounajjed T, Foo WC, Torbenson MS, Kleiner DE, Laird PW, Wheeler DA, McRee AJ, Bathe OF, Andersen JB, Bardeesy N, Roberts LR, Kwong LN. Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles. *Cell Rep*. 2017 Jun 27;19(13):2878-2880. PMID: 28658632.
41. **Cancer Genome Atlas Research Network**. Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma. *Cell*. 2017 Jun 15;169(7):1327-1341 PMID: 28622513
42. Farshidfar F, Zheng S, Gingras MC, Newton Y, Shih J, Robertson AG, Hinoue T, Hoadley KA, Gibb EA, Roszik J, Covington KR, Wu CC, Shinbrot E, Stransky N, Hegde A, Yang JD, Reznik E, Sadeghi S, Pedamallu CS, Ojesina AI, Hess JM, Auman JT, Rhie SK, Bowlby R, Borad MJ; **Cancer Genome Atlas Network**, Zhu AX, Stuart JM, Sander C, Akbani R, Cherniack AD, Deshpande V, Mounajjed T, Foo WC, Torbenson MS, Kleiner DE, Laird PW, Wheeler DA, McRee AJ, Bathe OF, Andersen JB, Bardeesy N, Roberts LR, Kwong LN. : Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles. *Cell Rep*. 2017 Mar 14;18(11):2780-2794 PMID: 28297679
43. Cherniack AD, Shen H, Walter V, Stewart C, Murray BA, Bowlby R, Hu X, Ling S, Soslow RA, Broaddus RR, Zuna RE, Robertson G, Laird PW, Kucherlapati R, Mills GB; **Cancer Genome Atlas Research Network**, Weinstein JN, Zhang J, Akbani R, Levine DA. Integrated Molecular Characterization of Uterine Carcinosarcoma. *Cancer Cell*. 2017 Mar 13;31(3):411-423 PMID: 28292439
44. **Cancer Genome Atlas Research Network**. The Molecular Taxonomy of Primary Prostate Cancer. *Cell*. 2015 Nov 5;163(4):1011-25. PMID: 26544944
45. Ciriello G, Gatza ML, Beck AH, Wilkerson MD, Rhie SK, Pastore A, Zhang H, McLellan M, Yau C, Kandoth C, Bowlby R, Shen H, Hayat S, Fieldhouse R, Lester SC, Tse GM, Factor RE, Collins LC, Allison KH, Chen YY, Jensen K, Johnson NB, Oesterreich S, Mills GB, Cherniack AD, Robertson G, Benz C, Sander C, Laird PW, Hoadley KA, King TA; **TCGA Research Network**, Perou CM. Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer. *Cell*. 2015 Oct 8;163(2):506-19. PMID: 26451490
46. **Cancer Genome Atlas Network**. Genomic Classification of Cutaneous Melanoma. *Cell*. 2015 Jun 18;161(7):1681-96. PMID: 26091043
47. **Cancer Genome Atlas Network**. Comprehensive genomic characterization of head and neck squamous cell carcinomas. *Nature*. 2015 Jan 29;517(7536):576-82. PMCID: PMC4311405. Selected for cover.
48. **Cancer Genome Atlas Research Network**, Brat DJ, Verhaak RG, Aldape KD, Yung WK, Salama SR, Cooper LA, Rheinbay E, Miller CR, Vitucci M, Morozova O, Robertson AG, Noushmehr H, Laird PW, Cherniack AD, Akbani R, Huse JT, Ciriello G, Poisson LM, Barnholtz-Sloan JS, Berger MS, Brennan C, Colen RR, Colman H, Flanders AE, Giannini C, Grifford M, Iavarone A, Jain R, Joseph I, Kim J, Kasaian K, Mikkelsen T, Murray BA, O'Neill BP, Pachter L, Parsons DW,

Sougnéz C, Sulman EP, Vandenberg SR, Van Meir EG, von Deimling A, Zhang H, Crain D, Lau K, Mallery D, Morris S, Paulauskis J, Penny R, Shelton T, Sherman M, Yena P, Black A, Bowen J, Dicostanzo K, Gastier-Foster J, Leraas KM, Lichtenberg TM, Pierson CR, Ramirez NC, Taylor C, Weaver S, Wise L, Zmuda E, Davidsen T, Demchok JA, Eley G, Ferguson ML, Hutter CM, Mills Shaw KR, Ozenberger BA, Sheth M, Sofia HJ, Tarnuzzer R, Wang Z, Yang L, Zenklusen JC, Ayala B, Baboud J, Chudamani S, Jensen MA, Liu J, Pihl T, Raman R, Wan Y, Wu Y, Ally A, Auman JT, Balasundaram M, Balu S, Baylin SB, Beroukheim R, Bootwalla MS, Bowlby R, Bristow CA, Brooks D, Butterfield Y, Carlsen R, Carter S, Chin L, Chu A, Chuah E, Cibulskis K, Clarke A, Coetzee SG, Dhalla N, Fennell T, Fisher S, Gabriel S, Getz G, Gibbs R, Guin R, Hadjipanayis A, Hayes DN, Hinoue T, Hoadley K, Holt RA, Hoyle AP, Jefferys SR, Jones S, Jones CD, Kucherlapati R, Lai PH, Lander E, Lee S, Lichtenstein L, Ma Y, Maglinte DT, Mahadeshwar HS, Marra MA, Mayo M, Meng S, Meyerson ML, Mieczkowski PA, Moore RA, Mose LE, Mungall AJ, Pantazi A, Parfenov M, Park PJ, Parker JS, Perou CM, Protopopov A, Ren X, Roach J, Sabedot TS, Schein J, Schumacher SE, Seidman JG, Seth S, Shen H, Simons JV, Sipahimalani P, Soloway MG, Song X, Sun H, Tabak B, Tam A, Tan D, Tang J, Thiessen N, Triche T Jr, Van Den Berg DJ, Veluvolu U, Waring S, Weisenberger DJ, Wilkerson MD, Wong T, Wu J, Xi L, Xu AW, Yang L, Zack TI, Zhang J, Aksoy BA, Arachchi H, Benz C, Bernard B, Carlin D, Cho J, DiCara D, Frazer S, Fuller GN, Gao J, Gehlenborg N, Haussler D, Heiman DI, Iype L, Jacobsen A, Ju Z, Katzman S, Kim H, Knijnenburg T, Kreisberg RB, Lawrence MS, Lee W, Leinonen K, Lin P, Ling S, Liu W, Liu Y, Liu Y, Lu Y, Mills G, Ng S, Noble MS, Paull E, Rao A, Reynolds S, Saksena G, Sanborn Z, Sander C, Schultz N, Senbabaoglu Y, Shen R, Shmulevich I, Sinha R, Stuart J, Sumer SO, Sun Y, Tasman N, Taylor BS, Voet D, Weinhold N, Weinstein JN, Yang D, Yoshihara K, Zheng S, Zhang W, Zou L, Abel T, Sadeghi S, Cohen ML, Eschbacher J, Hattab EM, Raghunathan A, Schniederjan MJ, Aziz D, Barnett G, Barrett W, Bigner DD, Boice L, Brewer C, Calatozzolo C, Campos B, Carlotti CG Jr, Chan TA, Cuppini L, Curley E, Cuzzubbo S, Devine K, DiMeco F, Duell R, Elder JB, Fehrenbach A, Finocchiaro G, Friedman W, Fulop J, Gardner J, Hermes B, Herold-Mende C, Jungk C, Kendler A, Lehman NL, Lipp E, Liu O, Mandt R, McGraw M, Mclendon R, McPherson C, Neder L, Nguyen P, Noss A, Nunziata R, Ostrom QT, Palmer C, Perin A, Pollo B, Potapov A, Potapova O, **Rathmell WK**, Rotin D, Scarpace L, Schilero C, Senecal K, Shimmel K, Shurkhay V, Sifri S, Singh R, Sloan AE, Smolenski K, Staugaitis SM, Steele R, Thorne L, Tirapelli DP, Unterberg A, Vallurupalli M, Wang Y, Warnick R, Williams F, Wolinsky Y, Bell S, Rosenberg M, Stewart C, Huang F, Grimsby JL, Radenbaugh AJ, Zhang J. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. *N Engl J Med*. 2015 Jun 25;372(26):2481-98. PMID: 26061751

49. Parfenov M, Peadamallu CS, Gehlenborg N, Freeman SS, Danilova L, Bristow CA, Lee S, Hadjipanayis AG, Ivanova EV, Wilkerson MD, Protopopov A, Yang L, Seth S, Song X, Tang J, Ren X, Zhang J, Pantazi A, Santoso N, Xu AW, Mahadeshwar H, Wheeler DA, Haddad RI, Jung J, Ojesina AI, Issaeva N, Yarbrough WG, Hayes DN, Grandis JR, El-Naggar AK, Meyerson M, Park PJ, Chin L, Seidman JG, Hammerman PS, Kucherlapati R; **Cancer Genome Atlas Network**. Characterization of HPV and host genome interactions in primary head and neck cancers. *Proc Natl Acad Sci U S A*. 2014 111(43):15544-9. PMID: PMC4217452.
50. **Cancer Genome Atlas Research Network**. Integrated genomic characterization of papillary thyroid carcinoma. *Cell*. 2014 159(3):676-90. PMID: PMC4243044

51. **Cancer Genome Atlas Research Network.** Comprehensive molecular profiling of lung adenocarcinoma. *Nature*. 2014 Jul 31;511(7511):543-50. PMID: 25079552
52. **Cancer Genome Atlas Research Network.** Comprehensive molecular characterization of gastric adenocarcinoma. *Nature*. 2014 513(7517):202-9. PMCID: PMC 4170219.
53. **Cancer Genome Atlas Research Network,** Integrated genomic characterization of endometrial carcinoma. *Nature*. 497:67-73, 2013. PMID: 23636398. *Collaborator, indexed as W. Rathmell or Kimryn Rathmell.
54. **The Cancer Genome Atlas Network.** Comprehensive molecular portraits of human breast tumours. *Nature*. 490(7418):61-70, 2012. PMID: 23000897. Collaborator. *Indexed as Kimryn Rathmell, W.
55. **Cancer Genome Atlas Research Network.** Comprehensive genomic characterization of squamous cell lung cancers. *Nature*. 489(7417):519-25, 2012. PMID: 22960745. Collaborator. *Indexed as Kimryn Rathmell, W.

Review Articles (peer reviewed)

1. Choueiri TK, Atkins MB, Bakouny Z, Carlo MI, Drake CG, Jonasch E, Kapur P, Lewis B, Linehan WM, Mitchell MJ, Pal SK, Pels K, Poteat S, **Rathmell WK**, Rini BI, Signoretti S, Tannir N, Uzzo R, Wood CG, Hammers HJ. Summary From the First Kidney Cancer Research Summit, September 12-13, 2019: A Focus on Translational Research. *J Natl Cancer Inst*. 2021 Mar 1;113(3):234-243. PMID: 32359162; PMCID: PMC7936057.
2. Rathmell JC, **Rathmell WK**. Pushing the boundaries with collision collaboration: the marriage of ideas. *J Clin Invest*. 2021 Jan 19;131(2):e145964. PMID: 33463534; PMCID: PMC7810468.
3. Rini B, Abel EJ, Albiges L, Bex A, Brugarolas J, Bukowski RM, Coleman JA, Drake CG, Figlin RA, Futreal A, Hammers H, Powles T, **Rathmell WK**, Ricketts CJ, Turajlic S, Wood CG, Leibovich BC. Summary from the Kidney Cancer Association's Inaugural Think Thank: Coalition for a Cure. *Clin Genitourin Cancer*. 2020 Nov 14:S1558-7673(20)30234-2. doi: 10.1016/j.clgc.2020.10.005. Epub ahead of print. PMID: 33358149.
4. Jonasch E, Walker CL, **Rathmell WK**. Clear cell renal cell carcinoma ontogeny and mechanisms of lethality. *Nat Rev Nephrol*. 2020 Nov 3. doi: 10.1038/s41581-020-00359-2. Epub ahead of print. PMID: 33144689.
5. Chahoud J, McGettigan M, Parikh N, Boris RS, Iliopoulos O, **Rathmell WK**, Daniels AB, Jonasch E, Spiess PE; International VHL Surveillance Guidelines Consortium-Renal Committee. Evaluation, diagnosis and surveillance of renal masses in the setting of VHL disease. *World J Urol*. 2020 Sep 16. doi: 10.1007/s00345-020-03441-3. Epub ahead of print. PMID: 32936333.
6. Bacigalupa ZA, **Rathmell WK**. Beyond glycolysis: Hypoxia signaling as a master regulator of alternative metabolic pathways and the implications in clear cell renal cell carcinoma. *Cancer Lett*. 2020 Oct 1;489:19-28. doi: 10.1016/j.canlet.2020.05.034. Epub 2020 Jun 5. PMID: 32512023; PMCID: PMC7429250.
7. Moslehi J, **Rathmell WK**. The 2019 Nobel Prize honors fundamental discoveries in hypoxia response. *J Clin Invest*. 2020 Jan 2;130(1):4-6. PMID: 31763994

8. Chappell JC, Payne LB, **Rathmell WK**. Hypoxia, angiogenesis, and metabolism in the hereditary kidney cancers. *J Clin Invest*. 2019 Feb 1;129(2):442-451. PMID: 30614813 PMCID: PMC6355237
9. **Rathmell WK**, Rathmell JC, Linehan WM. Metabolic Pathways in Kidney Cancer: Current Therapies and Future Directions. *J Clin Oncol*. 2018 Oct 29;JCO2018792309. doi: 10.1200/JCO.2018.79.2309. [Epub ahead of print]
10. Msaouel P, Hong AL, Mullen EA, Atkins MB, Walker CL, Lee CH, Carden MA, Genovese G, Linehan WM, Rao P, Merino MJ, Grodman H, Dome JS, Fernandez CV, Geller JI, Apolo AB, Daw NC, Hodges HC, Moxey-Mims M, Wei D, Bottaro DP, Staehler M, Karam JA, **Rathmell WK**, Tannir NM. Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients with Renal Medullary Carcinoma. *Clin Genitourin Cancer*. 2018 Sep 12. pii: S1558-7673(18)30384-7. [Epub ahead of print] PMID: 30287223
11. de Cubas AA, **Rathmell WK**. Epigenetic modifiers: activities in renal cell carcinoma. *Nat Rev Urol*. 2018 Oct;15(10):599-614. Review. PMID: 30030490
12. Ghatalia P, **Rathmell WK**. Systematic Review: ClearCode 34 - A Validated Prognostic Signature in Clear Cell Renal Cell Carcinoma (ccRCC). *Kidney Cancer*. 2018;2(1):23-29. PMID: 30320241
13. Ding L, Bailey MH, Porta-Pardo E, Thorsson V, Colaprico A, Bertrand D, Gibbs DL, Weerasinghe A, Huang KL, Tokheim C, Cortés-Ciriano I, Jayasinghe R, Chen F, Yu L, Sun S, Olsen C, Kim J, Taylor AM, Cherniack AD, Akbani R, Suphavitai C, Nagarajan N, Stuart JM, Mills GB, Wyczalkowski MA, Vincent BG, Hutter CM, Zenklusen JC, Hoadley KA, Wendl MC, Shmulevich L, Lazar AJ, Wheeler DA, Getz G; **Cancer Genome Atlas Research Network**. Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics. *Cell*. 2018 Apr 5;173(2):305-320.e10. PMID: 29625049
14. Weyandt JD, Thompson CB, Giaccia AJ, **Rathmell WK**. Metabolic Alterations in Cancer and Their Potential as Therapeutic Targets. *Am Soc Clin Oncol Educ Book*. 2017;37:825-832.. Review. PMID: 28561705
15. Beckermann KE, Sharma D, Chaturvedi S, Msaouel P, Abboud MR, Allory Y, Bourdeaut F, Calderaro J, de Cubas AA, Derebail VK, Hong AL, Naik RP, Malouf GG, Mullen EA, Reuter VE, Roberts CWM, Walker CL, Wood CG, DeBaun MR, Van Poppel H, Tannir NM, **Rathmell WK**. Renal Medullary Carcinoma: Establishing Standards in Practice. *J Oncol Pract*. 2017 Jul;13 PMID: 28697319
16. Reinfeld BI, **Rathmell WK**. Untangling ccRCC prognosis with SLINKY. *Oncotarget*. 2017 Mar 21;8(12):18620-18621. PMID: 28220033
17. Siska PJ, Beckermann KE, **Rathmell WK**, Haake SM. Strategies to overcome therapeutic resistance in renal cell carcinoma. *Urol Oncol*. 2017 Mar;35(3):102-110. PMID: 28089416
18. Haake SM, **Rathmell WK**. Renal cancer subtypes: Should we be lumping or splitting for therapeutic decision making? *Cancer*. 2017 Jan 1;123(2):200-209. PMID: 27861752
19. Haake SM, Weyandt JD, **Rathmell WK**. Insights into the Genetic Basis of the Renal Cell Carcinomas from The Cancer Genome Atlas. *Mol Cancer Res*; 2016 14(7); 589-98. PMID: 27330105 PMCID: PMC4955752

20. Chism DD, **Rathmell WK**. Kidney cancer: Rest ASSUREd, much can be learned from adjuvant studies in renal cancer. *Nat Rev Nephrol*. 2016 Jun;12(6):317-8. PMID: 27108841 PMCID: PMC4871728
21. Chang EH, Chong WK, Kasoji S, Dayton PA, **Rathmell WK**. Management of Indeterminate Cystic Kidney Lesions: Review of Contrast-Enhanced Ultrasound as a Diagnostic Tool. *Urology*. 2015 Oct 16. Jan; 87:1-10. PMID: 26483268
22. Block KI, Gyllenhaal C, Lowe L, Amedei A, Amin AR, Amin A, Aquilano K, Arbiser J, Arreola A, Arzumanyan A, Ashraf SS, Azmi AS, Benencia F, Bhakta D, Bilsland A, Bishayee A, Blain SW, Block PB, Boosani CS, Carey TE, Carnero A, Carotenuto M, Casey SC, Chakrabarti M, Chaturvedi R, Chen GZ, Chen H, Chen S, Chen YC, Choi BK, Ciriolo MR, Coley HM, Collins AR, Connell M, Crawford S, Curran CS, Dabrosin C, Damia G, Dasgupta S, DeBerardinis RJ, Decker WK, Dhawan P, Diehl AM, Dong JT, Dou QP, Drew JE, Elkord E, El-Rayes B, Fingleton MA, Felsher DW, Ferguson LR, Fimognari C, Firestone GL, Frezza C, Fujii H, Fuster MM, Generali D, Georgakilas AG, Gieseler F, Gilbertson M, Green MF, Grue B, Guha G, Halicka D, Helferich WG, Heneberg P, Hentosh P, Hirschey MD, Hofseth LJ, Holcombe RF, Honoki K, Hsu HY, Huang GS, Jensen LD, Jiang WG, Jones LW, Karpowicz PA, Keith WN, Kerkar SP, Khan GN, Khatami M, Ko YH, Kucuk O, Kulathinal RJ, Kumar NB, Kwon BS, Le A, Lea MA, Lee HY, Lichtor T, Lin LT, Locasale JW, Lokeshwar BL, Longo VD, Lyssiotis CA, MacKenzie KL, Malhotra M, Marino M, Martinez-Chantar ML, Matheu A, Maxwell C, McDonnell E, Meeker AK, Mehrmohamadi M, Mehta K, Michelotti GA, Mohammad RM, Mohammed SI, Morre DJ, Muralidhar V, Muqbil I, Murphy MP, Nagaraju GP, Nahta R, Niccolai E, Newsheem S, Panis C, Pantano F, Parslow VR, Pawelec G, Pedersen PL, Poore B, Poudyal D, Prakash S, Prince M, Raffaghello L, Rathmell JC, **Rathmell WK**, Ray SK, Reichrath J, Rezazadeh S, Ribatti D, Ricciardiello L, Robey RB, Rodier F, Rupasinghe HP, Russo GL, Ryan EP, Samadi AK, Sanchez-Garcia I, Sanders AJ, Santini D, Sarkar M, Sasada T, Saxena NK, Shackelford RE, Shantha Kumara HM, Sharma D, Shin DM, Sidransky D, Siegelin MD, Signori E, Singh N, Sivanand S, Sliva D, Smythe C, Spagnuolo C, Stafforini DM, Stagg J, Subbarayan PR, Sundin T, Talib WH, Thompson SK, Tran PT, Ungefroren H, Vander Heiden MG, Venkateswaran V, Vinay DS, Vlachostergios PJ, Wang Z, Wellen KE, Whelan RL, Yang ES, Yang H, Yang X, Yaswen P, Yedjou C, Yin X, Zhu J, Zollo M. Designing a broad-spectrum integrative approach for cancer prevention and treatment. *Semin Cancer Biol*. 2015 35 Suppl:S276-304. PMID: 26590477
23. **Rathmell KW***, Chen F, Creighton CJ. Genomics of chromophobe renal cell carcinoma: implications from a rare tumor for pan-cancer studies. *Oncoscience*. 2015 Feb 20;2(2):81-90. Review. PMID: 25859550 *Index error.
24. Goodson WH 3rd, Lowe L, Carpenter DO, Gilbertson M, Manaf Ali A, Lopez de Cerain Salsamendi A, Lasfar A, Carnero A, Azqueta A, Amedei A, Charles AK, Collins AR, Ward A, Salzberg AC, Colacci A, Olsen AK, Berg A, Barclay BJ, Zhou BP, Blanco-Aparicio C, Bagloli CJ, Dong C, Mondello C, Hsu CW, Naus CC, Yedjou C, Curran CS, Laird DW, Koch DC, Carlin DJ, Felsher DW, Roy D, Brown DG, Ratovitski E, Ryan EP, Corsini E, Rojas E, Moon EY, Laconi E, Marongiu F, Al-Mulla F, Chiaradonna F, Darroudi F, Martin FL, Van Schooten FJ, Goldberg GS, Wagemaker G, Nangami G, Calaf GM, Williams G, Wolf GT, Koppen G, Brunborg G, Kim Lyerly H, Krishnan H, Ab Hamid H, Yasaei H, Sone H, Kondoh H, Salem HK, Hsu HY, Park HH, Koturbash I, Miousse IR, Scovassi AI, Klaunig JE, Vondráček J, Raju J, Roman J, Wise JP Sr, Whitfield JR, Woodrick J, Christopher JA, Ochieng J, Martinez-Leal JF, Weisz J, Kravchenko J,

- Sun J, Prudhomme KR, Narayanan KB, Cohen-Solal KA, Moorwood K, Gonzalez L, Soucek L, Jian L, D'Abronzio LS, Lin LT, Li L, Gulliver L, McCawley LJ, Memeo L, Vermeulen L, Leyns L, Zhang L, Valverde M, Khatami M, Romano MF, Chapellier M, Williams MA, Wade M, Manjili MH, Lleonart M, Xia M, Gonzalez MJ, Karamouzis MV, Kirsch-Volders M, Vaccari M, Kuemmerle NB, Singh N, Cruickshanks N, Kleinstreuer N, van Larebeke N, Ahmed N, Ogunkua O, Krishnakumar PK, Vadgama P, Marignani PA, Ghosh PM, Ostrosky-Wegman P, Thompson P, Dent P, Heneberg P, Darbre P, Sing Leung P, Nangia-Makker P, Cheng QS, Robey RB, Al-Temaimi R, Roy R, Andrade-Vieira R, Sinha RK, Mehta R, Vento R, Di Fiore R, Ponce-Cusi R, Dornetshuber-Fleiss R, Nahta R, Castellino RC, Palorini R, Abd Hamid R, Langie SA, Eltom S, Brooks SA, Ryeom S, Wise SS, Bay SN, Harris SA, Papagerakis S, Romano S, Pavanello S, Eriksson S, Forte S, Casey SC, Luanpitpong S, Lee TJ, Otsuki T, Chen T, Massfelder T, Sanderson T, Guarnieri T, Hultman T, Dormoy V, Odero-Marah V, Sabbisetti V, Maguer-Satta V, **Rathmell WK**, Engström W, Decker WK, Bisson WH, Rojanasakul Y, Luqmani Y, Chen Z, Hu Z. Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead. *Carcinogenesis*. 2015 Jun;36 Suppl 1:S254-96. Review. PMID: 26106142
25. Hu Z, Brooks SA, Dormoy V, Hsu CW, Hsu HY, Lin LT, Massfelder T, **Rathmell WK**, Xia M, Al-Mulla F, Al-Temaimi R, Amedei A, Brown DG, Prudhomme KR, Colacci A, Hamid RA, Mondello C, Raju J, Ryan EP, Woodrick J, Scovassi AI, Singh N, Vaccari M, Roy R, Forte S, Memeo L, Salem HK, Lowe L, Jensen L, Bisson WH, Kleinstreuer N Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: focus on the cancer hallmark of tumor angiogenesis. *Carcinogenesis*. 2015 Jun;36 Suppl 1:S184-202. Review. PMID: 26106137
26. Wang Z, Dabrosin C, Yin X, Fuster MM, Arreola A, **Rathmell WK**, Generali D, Nagaraju GP, El-Rayes B, Ribatti D, Chen YC, Honoki K, Fujii H, Georgakilas AG, Nowsheen S, Amedei A, Niccolai E, Amin A, Ashraf SS, Helferich B, Yang X, Guha G, Bhakta D, Ciriolo MR, Aquilano K, Chen S, Halicka D, Mohammed SI, Azmi AS, Bilsland A, Keith WN, Jensen LD. Broad targeting of angiogenesis for cancer prevention and therapy. *Semin Cancer Biol*. 2015 Suppl:S224-43 PMID: 25600295
27. Debebe Z, **Rathmell WK**. Ror2 as a Therapeutic Target in Cancer. *Pharmacol Ther*. 2015 150:143-8. PMID: 25614331
28. Jonasch, E, Gao, JJ, **Rathmell WK**. Renal Cell Carcinoma. *BMJ*. 2014 Nov 10;349:g4797. PMID: 25385470
29. Chism, DD, **Rathmell, WK**. Seeing the Forest for the Trees: Kidney Oncogenomes Relate to Therapeutic Outcomes. *Clin Cancer Res*. 2014 20(7):1721-3 PMC4077661
30. **Rathmell, WK**, Brooks SA, Parker JS, Nielsen ME. Reply to Alexander S. Parker, Brad C. Leibovich, Jeanette E. Eckel-Passow, John C. Chevillie's Letter to the Editor re: Samira A. Brooks, A. Rose Brannon, Joel S. Parker, et al. ClearCode34: A Prognostic Risk Predictor for Localized Clear Cell Renal Cell Carcinoma. *Eur Urol* 2014;66:77-84. *Eur Urol*. 2014 Jul 15. S0302-2838(14)00630-7. PMID: 25037640
31. Keefe SM, Nathanson KL, **Rathmell WK**. The molecular biology of renal cell carcinoma. *Semin Oncol*. 2013 Aug;40(4):421-8. PMID: 23972705
32. Linehan WM, **Rathmell WK**. Kidney cancer. *Urol Oncol*. 2012 30(6):948-51. PMID: 23218074
33. Jonasch, E, Futreal, PA, Bailey, S, Kim, WY, Atkins, M, Sharma, P, Davis, IJ, Walker, CL, **Rathmell, WK**. State of the Science: update on renal cell carcinoma. *Mol Cancer Res*. 2012, 10(7):859-80. PMID: 22638109; PMC3399969

34. Khandani AH, **Rathmell WK**. Positron emission tomography in renal cell carcinoma: an imaging biomarker in development. *Semin Nucl Med*. 2012, 42(4):221-30. PMID: 22681671
35. Oosterwijk E, **Rathmell WK**, Junker K, Brannon AR, Pouliot F, Finley DS, Mulders PF, Kirkali Z, Uemura H, Belldegrun A. Basic research in kidney cancer. *Eur Urol*. 2011 Oct;60(4):622-33. PMID: 21741760
36. Rasmussen, N and **Rathmell, WK**. Looking beyond inhibition of VEGF/mTOR: Emerging targets for renal cell carcinoma drug development. *Current Clinical Pharmacology*. 2011 Aug;6(3):199-206. PMID: 21470103
37. Hacker, KE, **Rathmell, WK**. Emerging molecular classification in RCC: implications for drug development. *Targeted Oncology*. 5(2):75-84, 2010. PMID: 20645016
38. Brannon, AR, **Rathmell, WK**. Renal cell carcinoma, where will the state of the art lead us? *Current Oncology Reports*. 2010;12(3):193-201 PMID: 20425079
39. **Rathmell, WK**, and Godley, PA. Updates in Renal Cell Carcinoma. *Current Opinion in Oncology*. 2010;22(3):250-6. PMID: 20154618
40. **Rathmell, WK**, Pruthi, RS, Wallen, E. Neoadjuvant treatment of renal cell carcinoma. *Urol. Onc*. 2010. 28(1):69-73 PMID: 20123351
41. **Rathmell, WK**, Cowey, CL, and Fielding, J. Reply: Is objective response rate completely objective in kidney cancer? Improving radiographic assessment of targeted therapy in renal cell carcinoma. *Urology*, 2009. PMID: 19931124
42. Cowey, CL and **Rathmell, WK**. VHL gene mutations in renal cell carcinoma: role as a biomarker of disease outcome and drug efficacy. *Curr Oncol Rep*, 11: 94-101, 2009. PMID: 19216840
43. Cowey, CL and **Rathmell, WK**. Using Molecular Biology to Develop Drugs for Renal Cell Carcinoma. *Expert Opinion on Drug Discovery* 3(3): 311-327, 2008. PMID: 20648240
44. Rini, BI, **Rathmell, WK**, and Godley, P. Renal cell carcinoma. *Curr Opin Oncol*, 20: 300-306, 2008. PMID: 18391630
45. **Rathmell, WK** and Chen, S. VHL inactivation in renal cell carcinoma: implications for diagnosis, prognosis and treatment. *Expert Rev Anticancer Ther*, 8: 63-73, 2008. PMID: 18095884
46. Rini, BI and **Rathmell, WK**. Biological aspects and binding strategies of vascular endothelial growth factor in renal cell carcinoma. *Clin Cancer Res*, 13: 741s-746s, 2007. PMID: 17255303
47. **Rathmell, WK**, Martz, CA, and Rini, BI. Renal cell carcinoma. *Curr Opin Oncol*, 19: 234-240, 2007. PMID: 17414642
48. Rini, BI, Campbell, SC, and **Rathmell, WK**. Renal cell carcinoma. *Curr Opin Oncol*, 18: 289-296, 2006. PMID: 16552243
49. **Rathmell, WK**, Wright, TM, and Rini, BI. Molecularly targeted therapy in renal cell carcinoma. *Expert Rev Anticancer Ther*, 5: 1031-1040, 2005. PMID: 16336094
50. **Rathmell, WK** and Simon, MC. VHL: oxygen sensing and vasculogenesis. *J Thromb Haemost*, 3: 2627-2632, 2005. PMID: 15975138
51. **Rathmell, WK**, Godley, PA, and Rini, BI. Renal cell carcinoma. *Curr Opin Oncol*, 17: 261-267, 2005. PMID: 15818172
52. **Rathmell, WK** and Godley, PA. Renal cell carcinoma. *Curr Opin Oncol*, 16: 247-252, 2004. PMID: 15069321

Books and chapters

1. Lim, A and **Rathmell, WK** Chromophobe Renal Cell Carcinoma. In Prognostic and Predictive Biomarkers in Renal Cell Carcinoma, 2nd Edition. Ed. Nizar Tannir. 2018.
2. Rose, T and **Rathmell, WK** Biomarkers for Renal Cell Carcinoma. In Renal Cell Carcinoma: Principles and Practice, 2nd ed. Eds. Primo Lara and Eric Jonasch. 2015.
3. Ferguson, JE, Wallen, EM, and **Rathmell, WK**. Kidney Cancer. In 9th Manual of Clinical Oncology. 2014
4. Chism, DD and **Rathmell, WK**. Prognostic and Predictive Biomarkers in Renal Cell Carcinoma (RCC). In Renal Cell Carcinoma. Ed. Nizar Tannir. 2014
5. **Rathmell, WK**. HIF biology in renal cell carcinoma. In Renal Cell Carcinoma: Biology, Prognostic Factors, and Therapeutic Targets. Eds. Robert Figlin, Brian Rini, and W. Kimryn Rathmell. 2012
6. Arreola, A and **Rathmell, WK**. Biology of RCC (VEGF, mTOR, immune aspects). In Renal cell carcinoma: clinical management. Eds. Brian Rini and Stephen Campbell. 2012
7. Li, M and **Rathmell, WK**. Biomarkers in renal cell carcinoma, ASCO Education Book, 2011.
8. Haake, SM and **Rathmell, WK**. The biology of renal cell carcinoma. In Emerging Cancer Therapeutics: Renal Cancer. Eds. Walter Stadler and Jame Abraham. 2011. Pages 1-20.
9. Li, M and **Rathmell, WK**. Biomarkers for renal cell carcinoma. In Renal cell carcinoma: Principles and Practice. Eds. Primo Lara and Eric Jonasch. 2011.
10. Oosterwijk, E, Belldegrun, A, Brannon, AR, Finley, DS, Junker, K, Pouliot, F, **Rathmell, WK** and Uemura, H. Basic Research in Kidney Cancer. In Kidney Cancer. Eds. Z. Kirkali and P. Mulders. 1st EAU-ICUD International Consultation on Kidney Cancer, Barcelona, 2010. Edition 2011. Pages 31-45
11. Reddy, A, Kronek, L-P, Brannon, AR, Seiler, M, Ganesan, S, **Rathmell, WK**, Bhanot, G. Predicting Cancer Survival Using Expression Patterns. In Medical Biostatistics for Complex Diseases. Emmert-Streib, F. and Dehmer, M. (eds.). pp. 305-330. 2010
12. Rini, BI and **Rathmell, WK**. Vascular Endothelial Growth Factor Ligand-Binding Agents. In Renal Cell Carcinoma, Rini, B. and Campbell, S. (eds.). pp. 203-210, 2009.
13. Amin, C and **Rathmell, WK**. Angiogenesis Biology in Metastatic Renal Cell Carcinoma. In Renal Cell Carcinoma, Rini, B. and Campbell, S. (eds.). pp. 191-202, 2009.
14. **Rathmell, WK** and Rini, BI. Biologic and Clinical Implications of VEGF Activity in Renal Cell Carcinoma. In Renal Cell Carcinoma, Bukowski, R., Motzer, R., and Figlin, R. (eds.). pp. 99-118. 2008.
15. **Rathmell, WK** and Godley, P. Testicular Cancer. In Netter's Internal Medicine. 2nd Edition. Runge, M. and Greganti, A. (eds.). pp. 614-622, 2008.
16. **Rathmell, WK**, Stadler, WM, Rini, BI. Rational Therapeutic Choices and Strategies for Patients with Metastatic Renal Cancer, ASCO Education Book, 7 typed pages, 2008.
17. **Rathmell, WK**. VHL Gene: Clinical Implications, In ASCO Education Book, pp. 239-244, 2007.
18. **Rathmell, WK**, Chu, G. Mechanisms for DNA double-strand break repair in eukaryotic cells. In Nickolof, J.A., Hoekstra, M.F. (eds.) DNA damage and repair, Vol. 2: DNA repair in higher eukaryotes, Humana Press, pp. 299-316, 1998

Un-refereed reviews, perspectives, editorials

1. Levine RL, **Rathmell WK**. COVID-19 impact on early career investigators: a call for action. *Nat Rev Cancer*. 2020 Jul;20(7):357-358. doi: 10.1038/s41568-020-0279-5. PMID: 32503987; PMCID: PMC7273376.
2. **Rathmell WK**. Disruptions in the realm of medical science. *J Clin Invest*. 2020 Jun 1;130(6):2731-2732. doi: 10.1172/JCI139912. PMID: 32478677; PMCID: PMC7260009.
3. Marr KA, **Rathmell WK**, Hawley JB, Guth KD. Empowering ASCI's support of physician-scientists through stronger institutional connections. *J Clin Invest*. 2019 Apr 1;129(4):1516-1518. PMID: 30932915 PMCID: PMC6436849
4. Martin DM, **Rathmell WK**, Tavazoie SF. Balancing dual demands on the physician-scientist workforce. *J Clin Invest*. 2018 Jul 16. [Epub ahead of print]. PMID: 30010627
5. **Rathmell, WK** Making Strides Against a Rare Disease: Renal Medullary Carcinoma in Focus. OncLive. June 8, 2017
6. **Rathmell, WK** Tumor Genomics Program. ASCO University. 2014. <http://university.asco.org/tumor-genomics-program>
7. **Rathmell, WK**. The importance of HIF in clear cell renal cell carcinoma. *Kidney Cancer Journal*. 7(2): 303-305, 2009.
8. **Rathmell, WK**. Comment on autophagy related to VHL gene as a strategy to develop cancer treatments, NPR Morning Edition. 2008
9. **Rathmell, WK**. Biomarkers guide choice in systemic treatment. *Kidney Cancer Journal*. 6(1): 208-212, 2008
10. **Rathmell, WK**. and Shaw R. mTOR: An Emerging Pathway in Cancer, Novartis Internal Training Module. 2008.
11. **Rathmell, WK**. ASCO Updates. Focus on Fellows and Junior Faculty, Participation in the annual meeting. 2005.
12. Draznin, J. Kidney cancer. An Interview with Dr. Kimryn Rathmell, www.Oncolink.com July, 2004.
13. **Rathmell, WK.**, and Van Dyke, T., Keystone Symposia, Mouse Models of Human Cancer Meeting Review. Investigational Drugs Database. Thomson Current Drugs Online, 2004

Meeting papers

1. Reddy, A., Brannon, AR, Seiler, M, Irgon, J, Ljungberg, B, Zhao, H, Brooks, JD, **Rathmell, WK**, Ganesan, S, Bhanot, G. A Predictor for Survival in Intermediate Grade Clear Cell Renal Cell Carcinoma. BioComp '09 Proceedings. 2009.

Thesis, PhD Biophysics:

1. **Rathmell, WK**. "Ku and DNA/PK in the repair of DNA double strand breaks", 1996, Stanford University

Invited Presentations:

1. Emory Cancer Center (pending)
2. Fox Chase Cancer Center (pending)
3. UNC Chapel Hill, Medicine Grand Rounds, May 13, 2021
4. Dana Farber Cancer Center, Kidney Cancer Seminar Series, April, 2021
5. Stanford University Cancer Center Frontiers in Oncology Seminar, February 16, 2021
6. Wistar Institute Distinguished Lectures in Cancer Research, November 24, 2020
7. American Society of Nephrology, HIF is Noble and Nobel, November 7, 2020
8. Vanderbilt MSTP, Learning to Pivot, October 1, 2020
9. Vanderbilt University Medical Center, Setting a vision for the DOM, Spring 2020
10. *Eugene P. Schonfeld Memorial Lecture*. Kidney Cancer Association International Meeting, Miami, FL. November 15, 2019
11. Dana Farber Cancer Center Urology Seminar Series, September 11, 2019
12. Oklahoma University Cancer Center Seminar, October 11, 2019
13. Kidney Cancer Association, Croatia, March 28-29, 2019
14. Virginia Tech Carilion Research Institute (VTCRI) *Distinguished Public Lecturer*. Roanoke, VA. Spring 2019
15. Madrid CNIO Research Council Distinguished Seminars Series. Madrid, Spain. March 8 2019
16. Roswell Park Cancer Institute, Cancer Genetics External Seminar Series. Buffalo, NY. June 22, 2019
17. Dana Farber Kidney SPORE seminar. January 7, 2019
18. MD Anderson Grand Rounds. Houston TX. January 14, 2019
19. Baylor College of Medicine, Cancer Center Seminar Series. Jan 7, 2019
20. Graceland updates on kidney cancer. Memphis, TN. November 9, 2018
21. VHL Alliance Annual Meeting (organizer and speaker). Houston, TX. October 6, 2018
22. University of Alabama Birmingham, Cancer Center Grand Rounds. September 10, 2018
23. Emory Winship Cancer Center Seminar. Genomic Instability in RCC. Atlanta, GA June 7, 2018
24. Vanderbilt Division of Nephrology Seminar. Kidney Cancer for Nephrologists. March, 2018
25. Oklahoma University Cancer Center Seminar Series. RCC. Oklahoma City, OK March 9, 2018
26. Lineberger Comprehensive Cancer Center Seminar Series, SETD2 a dual function methyltransferase (or more?). Chapel Hill, NC January, 2018
27. Cancer Center Grand Rounds, Indiana University, Indianapolis, IN Dec 8, 2017
28. Mass General Hospital Cancer Series. Epigenetics in RCC. Boston, MA Nov 30, 2017
29. University of Colorado Health Science Center. RCC Genomics. September 2017
30. AACR Molecular Biology in Clinical Oncology (Faculty). Renal Cell Carcinoma. Aspen, Co. July 27, 2017
31. ASCO Annual Meeting. Education Session. Targeting Metabolism in Cancer. Chicago, IL. June 5, 2017
32. Northwestern University Lurie Cancer Center Grand Rounds. Epigenetics of Kidney Cancer. Chicago, IL February 10, 2017
33. Vanderbilt Medical Alumni. Translational studies in cancer. Nashville, TN October 21, 2016

34. Vanderbilt Urology Conference. Renal Cell Carcinoma. Nashville, TN August 2016
35. Translational Research at the Bioinformatic Edge. Schloss Dagstuhl, Wadern, Germany, June 2016
36. Forbeck Focus Meeting on Renal Medullary Carcinoma, Nashville, TN, April 2016
37. Chromatin and transcriptional regulation in RCC. Cancer Symposium. Duke-NUS Singapore. Mar 2016.
38. ClearCode34, is it ready for prime time? Cancer Colloquium 2016. St. Andrews, Scotland. Feb 2016.
39. Translational Studies in RCC. Cancer Biology Science Hour. Vanderbilt University. Feb 2016
40. Translational Studies in RCC. Nephrology Faculty Series. Vanderbilt University. Jan 2016
41. Alterations in angiogenesis related to VHL mutation. Nanomedicine Symposium. Houston, TX. Jan 2016.
42. What Nephrologists should know about kidney cancer. American Society of Nephrology. Sand Diego, CA. Nov 2015
43. James Wilson Lectureship, University of Northern Iowa, Chemistry Department, Cedar Falls, IA, Oct 2015
44. New Directions in RCC, Forbeck Foundation Scholar Retreat, Lake Geneva, WI, Oct 2015
45. Balancing the career of an MD-PhD. UNC MSTP Retreat. Wrightsville Beach, NC. Aug 2015.
46. Targeting Notch pathway to overcome resistance to anti-angiogenic therapy in RCC, MD Anderson Cancer Center, Ann. Kidney Cancer Symposium, Houston, TX, May 2015
47. Epigenetics in Kidney Cancer. American Urologic Association. New Orleans, LA May 2015
48. Comparison of kidney cancers using The Cancer Genome Atlas. Lineberger Symposium. Chapel Hill, NC April 2015
49. Angiogenic and Metabolic Phenotypes in RCC. Cancer Metabolism. ChongQing, China. March 2015.
50. Using Kidney tissue to make disease assessment. Special conference on Acute Kidney Injury, NIDDK, Bethesda, MD, March 2015
51. Translational Studies in RCC. Cleveland Clinic. Cleveland, OH. February, 2015.
52. Translational Studies in RCC. Vanderbilt Ingram Cancer Center. Nashville, TN. December 2014
53. SETD2 Mutations in Clear Cell RCC. Society of Urologic Oncology, Bethesda, MD. December 2014.
54. Transcriptomics of VHL disease. VHL Alliance International Meeting. Madrid, Spain. October, 2014
55. RCC Genomics and Therapeutics. Novartis Pharmaceuticals, Basel, Switzerland. June 18 2014.
56. Weissman Institute. Renal Cell Carcinoma Translational Opportunities. Rehovot, Israel July 2014, (seminar canceled due to political situation—meeting held by Skype).
57. Transcriptional processing in RCC. University of Zurich (ETH). Zurich, Switzerland, April 12, 2014.
58. Epigenetic Reprogramming in RCC. Fredrich Meisner Institute, Basel Switzerland, May 8 2014. Pending
59. Doctors, Data, Disease. Institute for Pure and Applied Mathematics, UCLA. Feb 11-14, 2014.

60. Chromophobe Renal Cell Carcinoma. Society of Urologic Oncology. Bethesda, MD. Dec 2-3, 2013.
61. Navigating the Two-Body Problem. With Jeff Rathmell. Duke MSTP Retreat. Wrightsville Beach, NC September 29, 2013.
62. Strategies for Negotiation as Physician-Scientist. MSTP Keystone Meeting. Keystone, CO. July 26, 2013.
63. ClearCode Risk Stratification of RCC. ASCO Poster Discussion Session. Chicago, IL. June 4, 2013.
64. RCC Adjunctive Therapies Abstract Discussion Leader. ASCO. Chicago, IL. June 1, 2013.
65. Ethics Roundtable on Genomic Cancer Studies. ASCO Satellite Luncheon. Chicago, IL. May 31, 2013.
66. Translational Studies in RCC. Hettelman Award Lecture. Chapel Hill, NC. April 19, 2013.
67. RCC Translational Studies. UNC Pathology Grand Rounds. Chapel Hill, NC. March 21, 2013.
68. Moving forward with RCC Heterogeneity. MD Anderson SPORE Planning Meeting and External Advisory Board Meeting. Houston, TX. March 21, 2013.
69. Importing Heterogeneity into New Biomarker Studies. NCI Task Force Planning Meeting for RCC. Orlando, FL. February 16, 2013.
70. Unraveling RCC Heterogeneity. Society of Urologic Oncology Annual Meeting. Bethesda, MD. November 30, 2012.
71. SETD2 in RCC, Grand Rounds, University of Chicago, Chicago, IL. November 16, 2012
72. Translation of Genomic Findings to RCC Treatments. Society of Translational Medicine. Chapel Hill, NC. October 20, 2012.
73. Epigenetic Landscape of Renal Cell Carcinoma, Signaling Grand Rounds, Duke University, Durham, NC October 31, 2012
74. Next Steps in RCC Biology. Kidney Cancer Association Annual Meeting. Chicago, IL. October 6, 2012
75. Classifications of RCC. 2nd Annual Western NY and Southern Ontario Kidney Cancer Meeting. Roswell Park. Buffalo, NY May 12, 2012
76. Clear Cell RCC Classification, Sunnybrook Cancer Center, University of Toronto, May 10, 2012
77. Clinical Subtypes of RCC. Princess Margaret Hospital and Cancer Center. Toronto, ON May 9, 2011
78. High throughput analysis of renal cancers. MD Anderson Cancer Center. Houston, TX. March 22, 2012
79. Epigenetics and VHL disease. VHL international conference. MD Anderson Cancer Center, Houston, TX. February 12, 2012
80. Ror2 Kinase in Renal Cell Carcinoma. FASEB Symposium on Kinases and Phosphatases. Snowmass, CO. July 20, 2011.
81. Defining Molecular Subsets of Renal Cell Carcinoma. 16th Annual Congress on Molecular Oncology. Rhodes, Greece. October 7, 2011.
82. Renal Cell Carcinoma: Molecular Markers and Neoadjuvant Therapy. Landes Symposium. Chapel Hill, NC. June 18, 2011.

83. TCGA Update in Renal Cell Carcinoma. Kidney Cancer Association Annual Symposium. Chicago, IL. October 16, 2011.
84. Renal Cell Carcinoma. Biomarkers and Clinical Practice. ASCO Education Session. Chicago, IL. June 4, 2011.
85. Biology of Clear Cell Renal Cell Carcinoma. AACR Session. Orlando, FL. April 24, 2011.
86. Molecular Classification of Renal Cell Carcinoma. 1st annual MD Anderson Kidney Cancer Research Symposium. Houston, TX. March 25, 2011.
87. Dissecting complex signatures from renal cell carcinoma. Van Andel Research Institute Cancer Seminar Series. Grand Rapids, MI. February 23, 2011.
88. Segregating subtypes of clear cell renal cell carcinoma. 1st Western New York and Southern Ontario Kidney Cancer Symposium. Lewiston, NY. October 8, 2010.
89. Understanding Molecular Stratification of Renal Cell Carcinoma. MD Anderson Cancer Center GU Grand Rounds. August 19, 2010.
90. Neoadjuvant treatment of Renal cell carcinoma. Fourth Cambridge Conference on Innovations and Challenges in Renal Cancer. Cambridge, MA. August 13, 2010.
91. Molecular Stratification of Renal Cell Carcinoma. Dana Farber Cancer Center Kidney Cancer 5th Annual Symposium. Boston, MA. August 12, 2010.
92. Selecting Targeted Therapy for RCC, CME Series, June, 2010-present. University of Michigan VAMC, Ann Arbor, MI, Charles George VA Medical Center, Asheville, NC., VAMC Clarksville, WV (scheduled), VAMC Somerset, PA (scheduled), Karmanos Cancer Center, Detroit, MI (scheduled)
93. Biomarkers for Renal Cell Carcinoma. AACR Meeting, 2010. Washington DC. April 20 2010
94. Renal Cell Carcinoma Update. Queens Hospital Grand Rounds. New York, NY. March 15, 2010
95. ccRCC, not so clear anymore. Stanford Cancer Center Seminar Series. Stanford, CA. March 4, 2010
96. Cancer Biology Program Seminar Series. Duke Comprehensive Cancer Center. Durham, NC. February 26, 2010
97. Renal Cell Carcinoma. Walter Reed Army Hospital. Washington DC. February 19, 2010
98. Clear cell RCC: not so clear any more. Ohio State University, Molecular Carcinogenesis and Chemoprevention Seminar. Columbus, OH, December 17, 2009
99. Renal Cell Carcinoma: Morning Report (CME series): High Point Regional Health System, High Point, NC, East Carolina Medical Center, New Bern, NC, Dorn VA Medical Center, Columbia, SC, John B Amos Cancer Center, Columbus, GA, Zimmer Cancer Center, Wilmington, NC, Forsythe Medical Center, Winston-Salem, NC, October 2009-January 2010.
100. Adjunctive therapy for renal cell carcinoma. Nexavar Investigators meeting. Chicago, IL. October 8, 2009
101. Emerging biomarkers for renal cell carcinoma. Kidney Cancer Association, Chicago IL, September 24, 2009
102. Renal cell carcinoma, what every internist needs to know. Internal Medicine Symposium, Chapel Hill, NC. March 20, 2009.

103. Renal cell carcinoma: update 2009. University of Nevada Reno. Grand Rounds. Reno, NV. January, 2009.
104. Renal cell carcinoma and response to targeted therapy. University of Kansas, Topeka. CME update. January 16, 2009.
105. Neoadjuvant use of TKI prior to nephrectomy. Society for Urologic Oncology. Bethesda, MD. December 4, 2008.
106. Combinations of targeted therapy and immunotherapy in renal cell carcinoma. Immunotherapy Conference 2008. Havana, Cuba. November 10, 2008.
107. Renal Cell Carcinoma. University of Cincinnati, November 6, 2008.
108. Grand Rounds: Renal Cell Carcinoma. Cornell University, October 13, 2008.
109. Renal Cell Carcinoma: a new era of targeted therapy. CME accredited seminars. Maine Medical Center. Silver Springs MD, Birmingham, AL, Laurinberg, NC, Hendersonville, NC, October, 2008-February, 2009.
110. How does cytoreductive nephrectomy help? The science behind tumor reduction surgery. 7th Annual Kidney Cancer Association Meeting. Chicago, IL. September 26, 2008.
111. HIF1 vs HIF2 interplay in renal cell carcinoma. Forbeck Junior Forum. Lake Geneva, WI. September 12, 2008
112. Molecular Characteristics of Renal Cell Carcinoma Contributing to Response to Targeted Therapy. Rutgers University BIOMaps Symposium. New Brunswick, NJ. August 3, 2008.
113. Preclinical and Prognostic Biomarkers of Renal Cell Carcinoma. ASCO Annual Meeting. Chicago, IL. June 1, 2008.
114. Neoadjuvant Sorafenib for Advanced Renal Cell Carcinoma. Bayer Investigators Meeting. Chicago, IL. April 25, 2008.
115. Renal Cell Carcinoma. NC Pharmacology Assoc. Winston-Salem, NC. February 28, 2008
116. Ror2, a novel kinase in RCC. Forbeck Junior Forum. Lake Geneva, WI, September 14, 2007
117. Basic Biology for Clinicians. Third World Congress of Oncology. San Francisco, CA September 9, 2007
118. Renal Cell Carcinoma, Lessons learned from Tyrosine Kinase Inhibitors, one year from FDA approval. Landes Genitourinary Malignancy Symposium. Chapel Hill, NC June 15, 2007
119. Renal Cell Carcinoma, Clinical Update. Wake Medical Center, and Dorothea Dix Medical Center. Raleigh, NC. June 12, 2007.
120. VHL Gene: Clinical Implications, ASCO Annual Meeting, Expanded Education session. Chicago, IL. June 1, 2007.
121. Of mice and men: VHL pathogenesis in renal cell carcinoma. University of New Mexico, Albuquerque, NM. December 12, 2006.
122. Of mice and men: understanding VHL pathogenesis. Cleveland Clinic, Cleveland, OH. December 5, 2006.
123. Recent Advances in Understanding the Pathogenesis of Kidney Cancer. Current Trends in Genitourinary Malignancies. New York, NY. November 18, 2006.
124. Genetic Events in the Development of Renal Cell Carcinoma. UNC Genetics Retreat. Wrightsville Beach, NC. September 23, 2006.
125. Genetic Determinants in the Development of Renal Cell Carcinoma. Forbeck Junior Forum. Lake Geneva, WI, September 16, 2006.

126. Structure and Function of VHL in Renal Cell Carcinoma. 3rd International Congress on Kidney and Bladder Cancer. Orlando, FL. August 3, 2006
127. Advances in the Treatment of Advanced Renal Cell Carcinoma. Landes Symposium on Urologic Cancer. Chapel Hill, NC. June 23, 2006.
128. Mouse Models of Kidney Cancer. Kidney Cancer Association Annual Meeting (submitted abstract selected for oral presentation). Chicago, IL. October 21, 2005.
129. Genetic Determinants of Renal Cell Carcinoma. Forbeck Junior Forum. Lake Geneva, WI, September 17, 2005.
130. ASCO Update on Prostate Cancer and Renal Cell Carcinoma. North Carolina Oncology Association semiannual meeting, Greensboro, NC. August 6, 2005
131. Update on Treatment of Advanced Renal Cell Carcinoma, Symposium of Multidisciplinary Advances in the Treatment of Genitourinary Cancers, Chapel Hill, June 17, 2005.
132. Renal Cell Carcinoma, NorthEast Medical Center, Concord, NC, February 22, 2005.
133. Animal Modeling of RCC, Genetics Core Meeting, University of North Carolina, Feb 2005.
134. VHL: Oxygen sensing and vasculogenesis, Curriculum in Genetics and Molecular Biology Seminar Series. University of North Carolina, January 7, 2005.
135. VHL: Oxygen sensing and molecular targeting, Forbeck Foundation Forum on Molecularly Targeted Therapy. Hilton Head, SC. November 2004.
136. Genetic events in the development of renal cell carcinoma, MSTP Seminar Series, University of North Carolina at Chapel Hill, September 24, 2004.
137. Advances in the Treatment of Advanced Renal Cell Carcinoma. Symposium on 112.
138. Multidisciplinary Advances in the Treatment of Genitourinary Cancers, University of North Carolina at Chapel Hill, February 2004.
139. VHL Mutations in Human Cancers, Lineberger Cancer Center Symposia, University of North Carolina at Chapel Hill, September 2003.
140. VHL Mutations in Human Cancers, Ingram Cancer Center, Vanderbilt University, Nov 2002.
141. VHL Mutations in Tissue Specific Tumorigenesis, Division of Oncology, Washington University School of Medicine, October 2002.
142. Models of VHL Disease and Renal Cell Carcinoma, Lineberger Cancer Center Seminar Series, University of North Carolina at Chapel Hill, October 2002.
143. Molecular Models of VHL Disease, Pharmacology Seminar, Duke University, October 2002.
144. Functional and Tissue Specific Effects of VHL mutations, Abramson Cancer Center Symposium, University of Pennsylvania, September 2002.

Patents/Licensure:

- Methods and Compositions for Analysis of Clear Cell Renal Cell Carcinoma. Provisional Application Serial No. 61/287,986. UNC Ref. No. 10-0073.

Teaching record:

Primary Research Mentorships (Current position, Awards)

- | | | | |
|---------------------|-------|-------------|---------------------------|
| • D Gaines, MD, PhD | 2021- | Post-doc | Holmen Pathway Fellowship |
| • M Wolf | 2019- | PhD student | |

- Z Bacigalupa, PhD 2018- Post-doc T32 CA119925
- S Norris, PhD 2017-2018 Post-doc T32 CA009582
Current: Scientist, Calico Labs

- B Reinfeld 2017- MSTP student T32 GM007347, F30 CA247202
- A Lim 2016- MSTP student T32 GM007347
- E Terzo, PhD 2016-2018 Post-doc T32 CA119925
Current: Scientist, Constellation

- J Weyant, PhD 2016-2018 Post-doc T32 CA009582
Current: Staff Scientist, LabCorp

- K Beckermann,MDPhD 2015-2018 Fellow/Post-doc CRI Irvington Fellowship
Current: Instructor, Vanderbilt

- A de Cubas, PhD 2015- Post-doc T32 CA009582, ACS Postdoctoral
Fellowship

- Y-C Chiang, PhD 2014-2017 Post-doc T32 CA009156
Current: Staff Scientist, CRO
Novella, Adjunct UNC

- S Sundaram, PhD 2014-2015 Post-doc Current: USDA, Fargo, NC

- Z Debebe, PhD 2012-2014 Post-doc Lineberger Postdoc T32 CA009156
Merck Postdoc Fellowship
Current: Scientist, KBI Pharma

- H Horne, PhD 2011-2012 Post-doc Current: Lead Scientist, KBI
Pharma

- C Fahey, PhD 2012- MSTP Student CTSA KL2 Program
T32 GM008719, T32 CA07134
F30 CA192643-01
Gertrude Elion Award
PEO Scholar Award

- S Brooks, PhD, MPH 2011-2015 PhD student UNC Toxicology T32 ES007126
HHMI Med²Grad Translational
Medicine Program
Current: JHU/NIH postdoc

- K Hacker, MD, PhD 2010-2014 MSTP Student T32 GM008719, T32

			GM007092 T32 CA071341 Gertrude Elion Award Current: Urology resident, UNC
• A Arreola, PhD	2009-2014	PhD student	F31 CA154080 T32 Training Grant GM007092 Current: Lead Cytogenetic Analyst, Lab Corp
• N Rasmussen, PhD	2008-2013	PhD student	T32 HL069768 Postdoc, Texas A&M Current: Lecturer, Rice University
• CL Cowey, MD	2007-2009	Fellow	T32 HL007149 Current: Faculty Baylor University Sammons Cancer Center, SU2C Melanoma PI
• M DeSimone, PhD	2007-2011	PhD student	Current: Regeneron, Translational Scientist HHMI Med-Grad Translational Medicine Award
• AR Brannon, PhD	2006-2011	PhD student	Current: Faculty, MSKCC T32 CA071341 Postdoc: MSKCC, Cancer Genomics UNC Grad Student Merit Award NSF Award Honorable Mention
• CM Lee, MD PhD	2005-2009	MSTP student	Current: Faculty, Washington U. Med/Peds resident, Duke NIEHS F30 ES 015248 Keystone Travel Award PEO Scholar Award
• T Wright, PhD	2005-2010	PhD student	Current: Faculty, Salk Institute Postdoc: Duke Cancer Biology NCI F31 CA132543 Keystone Travel Award Biotechnology Institute Minority Fellows Program UNC Lineberger Grad

Fellow Award
Frank P Graham Honor Society

- S Chen, MD, PhD 2004-2011 Post-doc

VHL Family Alliance Fellowship
Current: Research Assoc Prof. UNC

Student Summer Preceptorships

- Whitney Brown, Vanderbilt University (2020)
- Edith Amason, Seewanee College (2019)
- Colby Williams, Vanderbilt University (2018)
- Anuj Bhatia, Vanderbilt University (2018)
- Deviyani Bajpai, University School of Nashville (2017)
- Robert Hapke, Vanderbilt University (2017)
- Stephen Himmelberg, Washington and Lee University (2015)
- Zachary Husk, University of North Georgia, (2013)
- Natalie Sutton, NC Central University (2012)
- Nzingha Saunders, NC Central University (2011)
- Melissa Ruiz, William and Mary (2007), med school Virginia Commonwealth, Now in residency
- Kate Hacker, Dartmouth College (2006), went on to MSTP at UNC, now a urology resident
- Ray Stadiem, UNC medical student (2005), Resident/Chief Resident Internal Medicine, Northwestern Univ. Current: Faculty, Carolinas Medical Center, Charlotte, NC

Undergraduate students

- Whitney Johnson, Biochemistry (Vanderbilt University 2019-)
- Colby Williams, (Vanderbilt University 2018-2020)
- Anuj Bhatia, (Vanderbilt University 2018-)
- Deviyani Bajpai, (Belmont University 2018-)
- Robert Hapke, Biochemistry (Vanderbilt 2017-2020) *Winner, most outstanding student in Biochemistry, 2019
- Madeline Gordon, Biology (Vanderbilt 2016-2017)
- Armando Corona, Postbac program, graduate of UNC Pembroke (2014-2015), went on to PhD training, Duke
- Sudarshan Mohan, Biostatistics/Biology (UNC 2011-2015)
- Oishee Sen, Anthropology (UNC 2010-2014), went on to medical school, UNC
- Alex Karamelegas, Biology, pre-med (UNC 2008-2009), went on to medical school, VCU
- Natalie Carraway, Chemistry, (UNC 2003-2005), now a technician at Duke

Graduate Supervision, Thesis Committees

- Jessica Roetman, Mary Philip Lab, Cancer Biology
- Alex Pfannenstein, Ian Macara Lab, Cell Biology
- Juan Rojas, Paul Dayton Lab, PhD Engineering 2018
- Zhi Hu, Vicky Bautch Lab, PhD Genetics 2016

- Aminah Dal, Ian Davis Lab-replaced on move to Vanderbilt
- Marybeth Anderson, Jen Jen Yeh Lab, PhD Genetics 2016
- Michael Iglesia, Chuck Perou Lab, PhD Genetics 2015
- Stephen McDaniel, Brian Strahl Lab-replaced on move to Vanderbilt
- David Wei, Buddy Weissman Lab, PhD Toxicology 2014
- Alicia Greenwalt, Cyrus Vizieri Lab-replaced on move to Vanderbilt
- Kate Coleman, Jeanette Cook Lab, PhD Genetics 2015
- Isaac Chan, Al Baldwin Lab/Anna Mae Diehl Lab, PhD Genetics 2012
- Sean Bailey, William Kim Lab, PhD Genetics 2014
- Christina Lamb, Toxicology program, PhD Toxicology 2013
- Jessica Sorrentino, Ned Sharpless Lab, PhD Toxicology 2013
- Becky Sinnott, Angelique Whitehurst Lab, PhD Pharmacology 2013
- Yolanda Whang, Mohanish Deshmukh Lab, PhD Cell Biology 2009
- Kim Peterman, Ned Sharpless Lab, PhD Genetics 2008
- Aaron Thorner, Chuck Perou Lab, PhD Genetics 2010
- Sara Hanna, William Kim Lab, PhD Genetics 2013
- Sarah Stein, Al Baldwin Lab, PhD Biology 2012
- George Chao, Chuck Perou Lab, PhD Genetics 2012
- Adam Kimple, Mohanish Deshmukh Lab, PhD Genetics 2011
- Brian Lew Teng, Anthony Means Lab, Duke University, PhD Pharmacol 2011

Vanderbilt Junior Faculty Mentoring (formal assignment)

- Dr. Naira Baregamian, Surgical Oncology (BWF SPIRE Scholar)
- Dr. P. Brent Ferrell, Hematology and Oncology (K23)
- Dr. Vivian Weiss, Pathology (K08)
- Dr. Scott Haake, Hematology and Oncology (K08)
- Dr. Katy Beckermann, Hematology and Oncology (CRI-Irvington, K12)
- Dr. David Chism, Hematology and Oncology
- Dr. Dolly Ann Padovani-Claudio, Ophthalmology (K08)
- Dr. Doug Johnson, Hematology and Oncology (K23)
- Dr. Jennifer Green, Hematology and Oncology
- Dr. Charles Caskey, Biomedical Engineering
- Dr. Elizabeth Davis, Hematology and Oncology

UNC Junior Faculty Mentoring (formal assignment)

- Dr. Emily Chang, MD, Nephrology
- Dr. Nate Hathaway, PhD, Medicinal Chemistry
- Dr. Qing Zhang, PhD, Pathology
- Dr. Stephanie Sarantopoulos, MD-PhD, Medicine/Immunology (Duke)
- Dr. Kristy Richards, PhD-MD, Medicine/Genetics (*deceased*)
- Dr. Carey Anders, MD, Medicine
- Dr. James Coghill, MD, Medicine/Immunology

Grants:

Active

R01CA198482 (MPI Rathmell/Davis/Strahl) 05/01/15 – 04/30/20 (NCE)
National Cancer Institute
Chromatin Maintenance in Cancer Progression
This multiPI project approaches the biochemical developments associated with DNA repair defects linked to SETD2 loss in cancer. (Submitted for renewal)

R01CA203012 (MPI Rathmell/Walker) 07/01/2016-06/30/2021
National Cancer Institute
Methyltransferase Contributions to Genomic Stability and Cancer
This proposal is a comparison of a novel bifunctional activity of SETD2 to act as a methyltransferase for histones as well as microtubules involved in mitotic spindle formation. We propose to examine the relationship of SETD2 mono-allelic and bi-allelic deficiency to patterns of genomic instability, and explore opportunities to target this deficiency as a therapeutic strategy for SETD2 mutant cancer.

K12 CA090625-16, NIH (PI Rathmell) 07/01/2011-06/30/2021
Vanderbilt Clinical Oncology Research Career Development Program (VCORCDP)
This award supports the career development of junior faculty cancer-focused translational researchers. *Supplement awarded to provide additional trainee in tumor immunology.
07/01/2018-06/30/2021.

R01 CA217987-01 (PI Jeff Rathmell) 04/01/2018-03/31/2023
Metabolic Barriers to T Cell Activation in Clear Cell Renal Cell Carcinoma

T32 CA217834-01 (PI Rathmell) 08/01/2018-07/31/2023
Vanderbilt Integrated Molecular Oncology Research Training Program (VIMO-RTP)
This award supports the career development of cancer-focused translational researchers in clinical training.

ORIEN New Oncologic Visionary Award (NOVA) (PI Ganesan) 08/01/19-07/31/22
Endogenous Retroviruses in Cancer Immunotherapy
Role: Co-I

Pending

Completed

CA160728P1 (MPI Jonasch, Rathmell, Johnson) 09/01/2017-08/31/2020
Department of Defense, Team Science Award

Prognostic and Predictive Markers of Immunogenicity in Renal Cell Carcinoma

This project is a Team Science investigation of tissue specific markers of immunogenicity examining archival samples at VUMC, the Tennessee Valley VA Medical Center, and MDACC.

AACR-Kure It Research Grant (PI Rathmell)

07/01/2018-06/30/2020

Immunosuppression in the RCC tumor microenvironment

This study examines the metabolic and exosome components of the microenvironment.

VUMC57787(U27DD001155)

09/30/2015-09/29/2016

ATHN/Centers for Disease Control

Community Counts: Public Health Surveillance for Bleeding Disorders

Subrecipient of the Cooperative Agreement with CDC and American Thrombosis and Hemostasis Network (ATHN) shall perform public health surveillance of patients with bleeding and clotting disorders

VUMC40097(H30MC24046) (Rathmell)

06/01/2012-05/31/2016

Health Resources and Services Administration

Comprehensive Hemophilia Diagnostic and Treatment Center from Health Resources and Services Administration This Agreement provides support funds for the Southeast Region's MCHB Bleeding Disorders Program.

VUMC04965(U27DD000862) (Rathmell)

09/30/2011-09/29/2016

Centers for Disease Control and Prevention

Public Health Surveillance for the Prevention of Complications of Bleeding and Clotting Disorders
Subrecipient of the Cooperative Agreement with CDC and American Thrombosis and Hemostasis Network (ATHN) shall perform public health surveillance of patients with bleeding and clotting disorders.

K24CA172355-01A1(PI Rathmell)

07/01/2013 – 06/30/2018

National Cancer Institute

Prospective Studies for Clinical Translation.

This proposal will support my continued efforts to mentor translational junior physician scientists in careers bridging clinical trials with genomic medicine.

R21CA184387-01 (PI Rathmell)

04/01/2015 – 03/31/2017 (NCE)

National Cancer Institute

Exploiting DLL4 inhibition as a mechanism to overcome resistance in ccRCC

This collaborative study with Vicki Bautch and Paul Dayton explores an innovative strategy to assess and overcome resistance to VEGFR TKI therapy in renal cell carcinoma.

Not Assigned, Forbeck Foundation (PI Rathmell)

08/01/2015-07/31/2017

Immune Cell Genomic and Metabolomic Profiling in RCC

Project examines the clonality of B and T cell subsets in RCC tumors.

UCRF INNOVATOR Award (PI Rathmell)	08/01/13 – 07/30/15	
UNC Lineberger (UCRF)		\$50,000
Examining DLL4 Inhibition in Renal Cell Carcinoma		
Assess Notch pathway targeted therapy in renal cell carcinoma.		
Not Assigned (PI Rathmell/Lieb/Davis)	11/01/12 – 12/31/15	
V Foundation		\$600,000 (over 3 years)
Reprogramming the Histone Code in Renal Cell Carcinoma		
This proposal develops a biochemical, genomic, and therapeutic approaches to reveal the impact of epigenetic reprogramming in kidney cancer, and develop strategies to reverse these changes.		
Not Assigned (PI J. Rathmell)	7/1/13 – 6/30/15	
Cancer Research Institute		\$200,000
Metabolic Immunosuppression of T cells in Clear Cell Renal Cell Carcinoma and anti-PD-1 Therapy		
This study examines the competition between tumor cells and resident tumor lymphocytes for nutrients and responsiveness of tumor lymphocytes to immune stimulation.		
Not Assigned (PI Rathmell)	06/01/10 – 05/31/14	
American Cancer Society		\$798,884
Ror2 Signaling in Renal Cell Carcinoma		
This proposal describes a project to elucidate the transcriptional regulation, functional signaling properties, and implications for human cancer of Ror2 kinase expression.		
LCCC1219 (PI Rathmell/Chong)	01/01/13 – 12/31/14	
NC TRaCS		\$45,000
Contract Enhanced Ultrasound to Detect Early Renal Cell Carcinomas		
This study will pilot the use of CEU (contrast enhanced ultrasound) as a risk stratification tool for patients at high risk for renal cell carcinoma.		
LCCC1213 (PI Rathmell)	07/01/12 – 06/30/14	
UNC-Siemens Partnership		\$30,000
Defining Molecular and Functional Imaging Correlates of RCC Biological Features		
This project will use MR-PET imaging to create a three dimensional map of tumor heterogeneous features, for molecular correlation with laboratory based biomarkers.		
1-R01-CA121781 (PI Rathmell)	07/01/07 – 6/30/13	
National Cancer Institute		\$190,000 (per yr, 5 years)
Genetic Events in the Development of Renal Cell Carcinoma		
Not Assigned (PI Rathmell)	10/15/11 – 10/14/13	
NCI Experimental Therapeutics (NExT) Program		\$700,000 (over 2 years)
Targeting Ror2 for Therapeutic Benefit		

Not Assigned (PI Rathmell)	08/01/10 – 07/31/12	
Cancer and Leukemia Group B		\$88,000
Molecular Stratification of Renal Cell Carcinoma to Predict Response to Treatment		
Not Assigned (PI Rathmell)	07/01/10 – 06/30/12	
AACR Landon Foundation INNOVATOR Award for Personalized Medicine		
Molecular Stratification of RCC for Improved Prognosis		
PI Murray	09/16/09 – 06/30/11	
Agency for Healthcare Res and Quality		\$500,000
Retrospective Evaluation of Outcomes of PET Scanning Using the National Oncologic PET Registry.		
PI Rathmell	8/01/07 – 8/31/09	
Bayer Pharmaceuticals		\$150,000
A Pilot Neoadjuvant Study of Sorafenib Treatment for Stage II or Greater Renal Cell Carcinoma		
This support funds a clinical trial effort to use develop multimodality therapy for renal cell carcinoma.		
PI Janzen/Rathmell	07/01/09 – 06/30/10	
North Carolina Translational and Clinical Sciences		\$50,000
Ror2: Bench to bedside		
This pilot project supports partial funding for a technician and graduate student to work on aspects of the Ror2 project generating preliminary data to develop Ror2 as a target for kinase inhibitor development.		
PI Rathmell/Cowey	06/01/08 – 05/30/09	
Lineberger Cancer Center		\$40,000
Metabolic Effects of HIF Expression on Renal Cell Carcinoma		
This proposal aims to evaluate the effects of HIF-1 vs HIF-2 on measures of metabolic activity in vitro, in vivo, and in patients as a potential indicator of response to targeted therapy.		
PI Rathmell	08/1/06 – 07/31/09	
Doris Duke Charitable Foundation		\$125,000
Renal Cell Carcinoma: Biologic Indicators of Response to Targeted Therapy		
The objectives in this research are to 1) identify genetic and molecular characteristics of renal cell carcinoma critical to the invasive potential of this disease, and 2) determine reproducible biomarkers or indicators of renal cell carcinoma response to therapy.		
PI Rathmell	07/01/06 – 06/30/07	
American Cancer Society		\$164,693
Genetic Events in Renal Cell Carcinoma		
This proposal was relinquished after one year due to overlap with the R01.		

PI Rathmell	07/01/05 – 06/30/06	
VHL Family Alliance		\$35,000
Models of VHL Disease		
This study proposed a novel strategy to engage somatic events in renal cells to mimic the development of RCC.		
PI Rathmell	06/01/05 – 05/30/06	
UNC School of Medicine		\$30,000
Building a Translational Program in Renal Cell Carcinoma		
This support funded a clinical and translational effort to develop a close interface between molecular science and the clinical trials program.		
PI Rathmell/Turner	06/01/04 – 05/30/05	
Lineberger Cancer Center		\$35,000
Cox-2 Expression in Renal Cell Carcinoma		
An investigation of Cox-2 as a HIF target gene and potential therapeutic target in renal cell carcinoma.		
PI Rathmell	07/01/03 – 06/30/08	
National Cancer Institute K08		\$105,000 (yearly, 5 years)
Functional and Tissue Specific Effects of VHL Mutation in Renal Cell Carcinoma		
This project launched our analysis of VHL disease associated mutations in in vitro and in vivo studies.		
PI Rathmell	08/01/03 – 07/31/05	
V Foundation		\$100,000
VHL Mutations in Renal Cell Carcinoma		
A comparative analysis of structurally distinct VHL mutations and how these distinctions participate in the development of renal cell carcinoma.		

Professional Service (include offices held and dates held):

To discipline

- American Society of Clinical Investigation
 - Associate Editor, Journal of Clinical Investigation (2012-2017)
 - Councilmember, Secretary-Treasurer (2014-2017)
 - Publications Committee (2017-2020, chair 2019)
 - Development Committee (2018-2022, chair 2018)
 - Advocacy Committee (2017-2018, founder, chair 2017)
 - Seldin-Smith Award Selection Committee (2021)
 - Harrington Prize Selection Committee (2019-2021)
 - Vice President (2017-2018), President Elect (2018-2019)
 - President (2019-2020)

- American Association for Cancer Research-member 2003-present
 - Faculty, AACR Molecular Biology in Clinical Oncology, Aspen, CO (2017)
- American Association for the Advancement of Science-member 2015-present
 - Fellow, elected 2021
- American Society of Clinical Oncology-member 2001-present
 - ASCO Nominating Committee (elected position, chair) 2018-2020
 - ASCO Education Committee, Tumor Biology 2014-2017 (track leader)
 - ASCO Ethics Committee 2011-2014
 - ASCO Cancer Education Committee, Fellows and Faculty Program 2008
 - ASCO Leadership Development Program 2010-2011
 - ASCO Career Development Committee 2006-2009
 - ASCO Self-evaluation program peer reviewer
 - ASCO Membership Committee 2009
- Alliance for Clinical Trials in Oncology
 - Alliance Scholar Selection Committee (2014)
- Burroughs Wellcome Foundation, CAMS Scientific Advisory Committee (2019-present)
 - Diversity Pipeline Workshop (2019)
- Damon Runyon Cancer Foundation
 - Clinical Research Investigator Award Review Committee (2020-present)
- FASEB
 - Board of Directors, Advisor (2017-2018)
- Forbeck Foundation
 - Focus meeting organizer “Histone biology in cancer” (2022)
 - Scholar Award Meeting Chair, Lake Geneva, WI (2015)
 - Focus meeting organizer “International Colloquium on Renal Medullary Carcinoma Nashville, TN (2016)
 - Scholar Selection Committee (2018-present)
 - Scientific Board of Directors (term begins fall 2020)
- KC CURE
 - Scientific Advisory Committee (2016-present)
- Kidney Cancer Association
 - Annual meeting, scientific programming committee (2013-16)
 - KCA Southeast Region Patient Survivor Conference (2013, 2014 Organizer)

- KCA MidSouth Patient and Survivor Conference (2016, 2017 Organizer)
- KCA Medical Steering Committee (2019-present)
- Women in Kidney Cancer (chair)
- National Urology Research Agenda (NURA)
 - Program member (2017)
- RMC Alliance
 - Founding member and co-chair (2016-present)
 - Scientific Program Organizing Committee, first annual meeting (2017)
- Society of Urologic Oncology-member 2011-present
 - Annual meeting, Kidney cancer program task force (2011, 2013, 2014)
 - Annual meeting, Kidney cancer program chair (2012)
 - Annual meeting, Scientific Planning Committee (2016, 2017)
- VHL Family Alliance
 - Clinical Trials Task Force (2012-2014)
 - VHLA Clinical Advisory Council (2014-2019)
 - VHL CGIP Research Proposal Committee (2016-2019)
 - VHL Alliance Research Council (2020-present)
 - VHL Alliance Annual Meeting Organizing Committee (2018)

Grant review study sections (non-NIH)

American Cancer Society, TBG Study Section, Permanent Member (2010-2017)

Department of Defense

CDMRP Integration Panel, permanent member (2010-2013)

CDMRP Kidney Cancer Research Program-Stakeholders Meeting (2017)

CDMRP Kidney Cancer Research Program Integration Panel (2017-)

CDMRP Kidney Cancer Research Program Integration Panel, chair (2018-2021)

Burroughs Wellcome Fund (noted above)

Damon Runyon Cancer Foundation (noted above)

Dutch Cancer Society, ad hoc reviewer (2010-2012)

Florida Department of Health, ad hoc reviewer (2010)

Federal Drug Administration, Orphan Products program, ad hoc reviewer (2009-2012)

Italian Ministry of Health, ad hoc reviewer (2009-2012)

Terry Fox Cancer Research Institute-Program Project Reviewer (2016)

National Institutes of Health

NCI Board of Scientific Advisors (2018-)

NCI Provocative Questions Basic Science Workshop (2019)
CSR Fellowship Panel Oncological Sciences F09B (2015-2018)
NIH BMCT-C Ad Hoc member (2013)
NIH NCI-J Ad Hoc member (2013, 2014, 2017)
NIH NCI-F09 Ad Hoc member (2015)
NIH MONC Ad Hoc member (2016)
NIH SEP 6 Review Committee, ZCA1 SRB-K (O1) (2017)

External Reviewer Urologic Oncology Branch, Genitourinary Oncology Branch (2015-)

NanoMedicine Roadmap Initiative, External Advisory Board (2011-2014)
NIH Kidney Cancer Task Force (2011-present)

The Cancer Genome Atlas Network-Tissue Source Site, Disease Advisor (2009-)
The Cancer Genome Atlas-Kidney Cancer Disease Working Group (2009-2011)
The Cancer Genome Atlas-Kidney Clear Cell Cancer Analysis Working Group (AWG), RNA analysis and clinical data leader (2011-2013), Papillary Kidney Cancer, AWG, RNA analysis and clinical data (2013-2014), Pheochromocytoma and Paraganglioma AWG, disease expert, writing group (2014-2017), Cholangiocarcinoma AWG (2014-2017)
The Cancer Genome Atlas-Chromophobe Kidney Cancer AWG, Co-chair (2012-2014)
The Cancer Genome Atlas-PanRCC AWG, Co-chair (2015-2018)

Manuscript Review

New England Journal of Medicine, Nature, Nature Medicine, Nature Communications, Cancer Research, Clinical Cancer Research, Molecular Cancer Research, Journal of Clinical Oncology, Proc Nat Acad Sci USA, Journal of Clinical Investigation, Cancer, Cancer Discovery, Molecular and Cellular Biology, Nature Reviews Clinical Oncology, PLoS Genetics, PLoS One, Journal of Urology, Urology, BMC Cancer, British Journal of Urology, European Urology, others

Editorial Boards

Journal of Clinical Investigation, Associate Editor, Editorial Board, 2012-2017
Journal of Clinical Investigation, Consulting Editor, 2017-
JCO-Precision Oncology, Editorial Board, 2016-
Cancer Research, Editorial Board, 2012-2015
Oncology Reports, Editorial Board, 2012-2015
Kidney Cancer, Editorial Board, 2016-

Academic Service

Within Vanderbilt University

Department of Biomedical Informatics Chair Search Committee (2021, chair)

Updated 03/13/2021

VMG Finance Committee (2020-present)
 VMG Board (2020-present)
 Executive Committee of the Executive Faculty (2020-present)
 Medical Center Medical Board (2020-present)
 Vanderbilt Transgender Medicine Initiative (2019-present)
 VU-VUMC Trans-Institutional Program Committee (2017-present), Task force (2020)
 Radiation Oncology Chair Search Committee (2019-2020)
 Cardiovascular Medicine Director Search Committee, Co-Chair (2020)
 Vanderbilt Cancer Committee (2019-present)
 Grievance Committees, Faculty Senate (2019, 2020)
 Search Committee, Department of Surgery Chair (2018)
 Faculty Affairs Promotions Committee (2017-2019)
 Grievance Committee, Faculty Senate (2018)
 Cancer Biology Program Executive Committee (2017-2019)
 Vanderbilt Faculty Research Scholar Selection Committee (2017-2020)
 Vanderbilt-Ingram Cancer Center, Cancer Education Advisory Committee (2017-present)
 Vanderbilt-Ingram Cancer Center, Executive Leadership Committee (2015-present)
 Vanderbilt University Medical Center, Strategic Planning Committee-Research Team (2018)
 Vanderbilt Department of Medicine Executive Committee (2015-)
 Vanderbilt Department of Medicine Compensation Plan Committee (2016-2017)
 Vanderbilt University Medical Center Strategic Planning Committee (2016)
 Vanderbilt-Ingram Cancer Center, Clinical Trials Office Steering Committee (2015-)
 Program Director and Steering Committee Leader, Vanderbilt Hemophilia Treatment Center
 (2017-2020)
 Medical Director, Vanderbilt Hemophilia Treatment Center (2016-2017)
 Clinical Leader, Vanderbilt Hereditary Kidney Cancer Risk Clinic (2016-present)
 Vanderbilt MSTP College Advisor (Avery-Cohen College, 2016-present)
 Vanderbilt Limited Submission Opportunity Reviewer (2016-2019)
 Medical Director, Hemophilia Treatment Center (2016-2017), Program Director (2017-2020)
 Oncology Care Model Steering Committee (2016-)
 Oncology Care Model Psycho-oncology Implementation Committee, chair (2016-)
 Oncology Clinical Leadership Committee (2015-)
 Hematology and Oncology Leadership Committee Chair (2015-2020)
 Hematology and Oncology Fellowship Steering Committee (2015-2020)

Within UNC-Chapel Hill

UNC Lineberger Cancer Center, Associate Director for Education and Training (2014-2015)
 UNC Lineberger Cancer Center, Faculty Director Tissue Procurement (2014-2015)
 School of Pharmacy, Faculty Search Committee (2014), Dr. Stephen Frye, Chair
 Department of Genetics Faculty Search Committee (2013), Dr. Rosann Farber, Chair
 Research Imaging Center Faculty Search Committee (2013), Dr. Weili Lin, Chair
 UNC MD-PhD program, Director for Translational Research (2012-2015)
 HHMI Translational Medicine MedEd/Grad Certificate Program, Clinical Director (2010-2015)

Translational Medicine Med²Grad External Advisory Committee (2016-present)
Translational Medicine, New PhD program planning committee (2011-2014)
UNC Hospital Strategic Planning Committee—subgroup leader (2011)
Biomedical and Biological Science Program Graduate students Admission Committee, member (2010-2011)
Lineberger Faculty Search Committee (2010-2013), member, Dr. Al Baldwin, chair
Oncology Junior Faculty Mentoring Program (2010-present), Director
Core Leadership Team, HHMI Med-into-Grad Program (2009-2014), co-director
Medicinal Chemistry Faculty Search Committee (2012), member, Dr. Jian Liu, Chair
Senior Nanotechnology Faculty Search Committee (2009-2011), member, Dr. Rudy Juliano, Chair
Sociology/Psychiatry Faculty Search Committee (2009-2010), member, Drs. Don Baucom and Ken Bollen, Co-chairs
Animal Models Core Committee, (2009-2015), member
Experimental Imaging Faculty Search Committee (2009), Dr. Weili Lin, Chair
UCRF Cancer Genetics Theme Team (2008-2010), Dr. Daniel Pomp, Chair
Genetics Faculty Search Committee (2008-2010), member
Sheps Center, Grant Review Committee (2008), member
Initiative to Maximize Student Diversity Task Force (2007), member
Lineberger Translational Grant Review Committee (2006-2008, 2010), member, (2011, 2015), chair
UNC Initiative to Maximize Student Diversity Committee, (2006-2013), member
UNC Protocol Review Committee, (2005-2010, 2013), member
Genetics and Molecular Biology Admissions Committee, (2005-2008), member
UNC MD/PhD Training Program Executive Board, (2004-2015), member
UNC MD/PhD Training Program Admissions Committee (2004-2015), member

Outside institutions

Dana Farber Cancer Institute
External Advisory Committee, SPORE in Kidney Cancer—PI: David McDermott
University of Pittsburgh Medical Center
External Advisory Committee, P01 on endothelial biology—PI: Michael Lotze
University of Chicago
External Advisory Committee, SOAR Program - PI: Funmi Olopade
External Advisory Committee, T32 in Oncology – PI: Funmi Olopade
MD Anderson Cancer Center
External Advisory Committee, T32 in Oncology – PI: Michael Davies
Emory University
External Advisory Committee, K12 in Oncology – PI: Christopher Flowers
Northwestern Lurie Cancer Center
External Advisory Committee, T32 in Oncology – PI: Hidayatullah G. Munshi
University of North Carolina
External Advisory Committee, T32 in Molecular Medicine—PI: Maureen Su

Consulting:

Novartis, Sales Training Consultant (2010)
AVEO Pharmaceuticals, Clinical and Biomarker Senior Advisory Board (2009-2012)
Wyeth Pharmaceuticals, Expert Advisory Panel (2008)
Onyx Pharmaceuticals, Expert Clinical Advisory Panel (2006-2007)
GSK Biomarkers Advisory Board (2011)
Best Doctors (2014-2019)
Aravive, Scientific Advisory Board (2019-present)